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The ovarian hormone progesterone influences many facets of uterine physiology through 
the transcriptional activity of progesterone receptor (PR). This body of work investigates the role 
of progesterone receptor targets heart and neural crest derivatives expressed 2 (HAND2) and 
insulin receptor substrate 2 (IRS2) in regulating uterine functions. Our lab has previously shown 
that the PR target HAND2 is a negative regulator of uterine epithelial proliferation and is 
hypermethylated and silenced in uteri from women diagnosed with endometrial hyperplasia and 
cancer.  The study presented in chapter 2 demonstrates that exposure to the environmental 
toxicant bisphenol-A (BPA) causes increased methylation at the Hand2 promoter and reduced 
HAND2 expression. BPA also stimulated expression of fibroblast growth factors (FGF), stromal 
derived factors that drive uterine epithelial proliferation. Increased expression of the pro-
proliferative FGFs coupled with decreased expression of the anti-proliferative HAND2 led to 
aberrant epithelial proliferation. This is notable in the uterine glands, the site of origin for 
endometrial hyperplasia and cancer, suggesting that environmental BPA exposure poses as a risk 
factor for these uterine conditions.  
We recently identified IRS2 as a direct target of PR in human endometrial stromal cells. 
IRS2 serves as an adaptor molecule for insulin and IGF1 receptors (IR and IGF1R, respectively). 
The study presented in chapter 3 explores the function of IRS2 during stromal differentiation. 
We find that IRS2, acting downstream of IR, is critical for inducing the expression of decidual 
markers and the changes in cell morphology characteristic of stromal differentiation. We also 
show that IRS2 promotes expression and membrane localization of glucose transporters (GLUT), 
allowing for increased glucose movement into the cell to meet the metabolic demands of 
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differentiation. This work provides insight into the metabolic shifts in differentiating stromal 
cells and the hormone regulated factors that mediate it. These findings may also shed light on the 
mechanisms underlying the infertility associated with conditions presenting with peripheral 
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The uterus is a female reproductive organ composed of three distinct layers, a mucosal 
inner layer known as the endometrium, a muscular layer known as the myometrium, and a 
serosal layer known as the perimetrium. The endometrium can be further divided into an 
epithelial compartment made up of the epithelial cells lining the endometrial glands and uterine 
lumen and a stromal compartment composed of a population of fibroblast cells. These 
compartments work together to establish and maintain pregnancy. For successful pregnancy, the 
uterus must undergo a series of structural and functional changes early in gestation to promote 
invasion of the embryo into maternal tissue (implantation) and conversion of the maternal tissue 
into a secretory structure that will support the embryo (decidualization). These changes are 
driven by the coordinated actions of 17β-estradiol and progesterone (1, 2). Understanding how 
these hormones drive the process of implantation and decidualization will help us better 
understand the underlying causes of infertility. 
BACKGROUND  
Steroid hormone receptors regulate uterine biology 
The endometrium undergoes dynamic changes throughout a woman’s reproductive life. 
Many of these changes are driven by steroid hormones estrogen and progesterone. Estrogen and 
progesterone are synthesized from cholesterol in the ovary and can diffuse into a target cell to act 
on their cognate receptors. The estrogen receptors, ERα and ERβ, and the progesterone receptors, 
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PR-A and PR-B, are members of the nuclear receptor family of transcription factors. Hormone 
binding activates the receptor, promoting receptor dimerization and binding to specific genomic 
sites to activate or repress the expression of their target genes. Through the use of chromatin 
immunoprecipitation coupled to high throughput sequencing, genome-wide binding sites of ER 
and PR have been identified, representing consensus sequences GGTCAnnnTGACC and 
AGAACAnnnTGTTCT, respectively (3, 4). Many of these binding sites occur at distal enhancer 
regions, which then form complexes with the proximal promoter through a chromosomal looping 
event (5, 6). 
The generation of mutant mouse models lacking functional ER or PR has provided great 
insight into the role of steroid hormone-regulated gene expression in the uterus during 
pregnancy. ERα is the predominant ER isoform that mediates critical uterine functions during the 
reproductive cycle and pregnancy. Its loss results in female infertility and insensitivity to the 
mitogenic effects of estrogen (7). Loss of ERβ, on the other hand, has no effect on uterine 
function but shows reduced fertility due to an ovarian defect (8). Generation of an epithelial-
specific deletion of ERα also results in female infertility (9). Interestingly, loss of epithelial ERα 
does not prevent estrogen-induced epithelial cell proliferation, suggesting that ERα action in the 
stroma is critical for mediating this event in a paracrine manner. These findings are supported by 
tissue recombination experiments performed by Cunha et al, who demonstrated the 
interdependency between the endometrial epithelium and (10, 11). 
PR knockout (PRKO) females are infertile due to an ovulation defect and uteri that are 
non-receptive to implanting embryos and fail to mount a decidual response during artificial 
decidualization (12). Uteri from PRKO mice are also hyperplastic, indicating that progesterone 
signaling is anti-proliferative. Mice lacking PR exclusively in the uterine epithelium are also 
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infertile (13). However, while one study showed that epithelial deletion of PR leads to persistent 
uterine epithelial proliferation, another group showed that epithelial PR is dispensable for the 
anti-proliferative effects of P on the uterine epithelium (13, 14). The findings of the later study 
are supported by tissue recombination experiments showing that uterine stromal PR is critical for 
suppressing estrogen induced uterine epithelial proliferation, while epithelial PR is dispensable 
(11). These data suggest epithelial proliferation is regulated by a paracrine mechanism involving 
stromal PR. 
Implantation  
The window of implantation represents a brief period of time where the uterus is 
receptive to the invading embryo. This state is achieved through the production of multiple 
signaling molecules produced in the epithelial and stromal compartments during the peri-
implantation period that help prepare the maternal tissue for embryo attachment and invasion. 
Many of these factors are regulated by estrogen and progesterone. In humans, the 28 day uterine 
cycle is divided into 3 phases: menses, the proliferative phase, and the secretory phase (15). 
During menses, the endometrial lining is sloughed in the absence of pregnancy. During the 
proliferative phase, elevated ovarian estrogen drives endometrial proliferation to thicken the 
endometrial lining.  The secretory phase begins after ovulation on day 14, and the hormonal 
profile shifts to elevated levels of progesterone and decreased estrogen produced from the 
ovaries. The window of implantation begins on cycle day 19 during the secretory phase, with 
implantation occurring 6-10 days after ovulation, when progesterone levels are elevated (16). In 
mice, the steroid hormone-regulated events leading to implantation are well defined. During days 
1-2 of pregnancy (day 1 corresponds to the detection of a copulatory plug), estrogen is the 
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predominant hormone driving proliferation of the luminal and glandular epithelium. Estrogen 
stimulation of the uterine stroma drives production of insulin-like growth factor 1 (IGF1) and a 
subset of fibroblast growth factors that act in a paracrine fashion to drive epithelial proliferation 
(17, 18). By day 4 of pregnancy, with the rise of progesterone secreted from the newly formed 
corpora lutea, the uterine epithelium shifts from a proliferative to a differentiated state and 
becomes receptive to embryo attachment. The cessation of epithelial proliferation is requisite to 
achieve a receptive state; stromal factors like muscle segment homeobox genes MSX1/2 and 
heart and neural crest derivatives-expressed protein 2 (HAND2) are critical in suppressing 
epithelial proliferation (18, 19).  
Development of a receptive uterus involves structural and functional remodeling of the 
uterine epithelium. During this process, the epithelial cells lose polarity through down-regulation 
of the cell-cell adhesion molecule E-cadherin, exhibit an inhibition of the cell surface 
glycoprotein mucin 1 (MUC1), and develop protrusions along the apical surface (20, 21, 22). As 
the uterus attains receptivity, the trophectoderm layer of the embryo can interact with the uterine 
luminal epithelium and begin invasion into the maternal tissue (1, 2). The process of 
implantation occurs in three stages; apposition, attachment, and invasion (2). Apposition 
represents the very first contact between the blastocyst and the maternal tissue. During the 
attachment phase, much stronger connections are made between the trophoblast cells of the 
blastocyst and the endometrial epithelium through receptor-ligand interactions, such as integrin 
αvβ3 on the surface of trophoblast cells interacting with its ligand osteopontin on the surface of 
endometrial epithelial cells (23). Once attached, the embryo begins the process of invasion, 
wherein trophoblast cells breach the epithelial layer and invade into the underlying stroma. The 
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invading trophoblast cells contact maternal spiral arteries and convert them to large, low 
resistance blood vessels to maintain a high rate of blood flow between mother and fetus (24). 
Decidualization 
During decidualization, the uterine stroma undergoes a process of extensive proliferation, 
differentiation, and vascularization to support the embryo during early pregnancy (1). In mice, 
this process is triggered by embryo implantation, whereas in humans, decidualization is initiated 
during the secretory phase of each uterine cycle, irrespective of the presence of a viable embryo 
(25). During decidualization, stromal cells undergo extensive morphological changes in the 
transformation to decidual cells. Undifferentiated stromal cells are fibroblastic with little 
cytoplasm and smaller elongated nuclei (25). Following transformation, decidual cells take on an 
epithelioid appearance with rounding of the nucleus, expansion of the cytoplasm, and 
accumulation of intracellular lipid and glycogen droplets (25). This transformation is driven by 
steroid hormones and the accumulation of cyclic adenosine monophosphate (cAMP) (25).  
Decidualization initiates in stromal cells underlying the luminal epithelium and surrounding 
terminal spiral arteries (1). In humans, this process prepares the endometrium for the implanting 
embryo, and in the event of pregnancy, decidualization will spread beyond the perivascular 
regions, throughout the entire endometrium (26). Decidual cells mediate multiple actions during 
early pregnancy, including production of growth factors and cytokines to support embryo 
development, promote vascular remodeling, and regulate trophoblast invasion (27, 28, 29). 
Factors produced by decidual cells are also critical for modulating the maternal immune response 
to ensure immunotolerance to the embryo (30).  Several factors are produced in abundance by 
decidual cells, including prolactin (PRL) and IGF-1 binding protein-1 (IGFBP1) (25). PRL 
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production increases at day 22 of the uterine cycle and is involved in stimulating trophoblast 
growth and invasion, preventing immune rejection, and regulating water movement across the 
amnion (31, 32, 33). IGFBP1 is also produced during the secretory phase of the uterine cycle, 
and during early pregnancy regulates IGF1 signaling and trophoblast migration (34, 35, 36). 
These markers serve as useful tools to determine a successful decidual response.  
Decidualization is necessary for successful pregnancy. In humans, in vitro 
decidualization of stromal cells from women experiencing recurrent pregnancy loss or from 
eutopic biopsies of women suffering from endometriosis show a blunted decidual response 
compared to cells from healthy patients (37, 38, 39). Successful decidualization is highly 
dependent on PR and the expression of PR targets (12).  Transgenic mouse models have 
demonstrated that conditional deletion of progesterone responsive targets like CEBPβ, BMP2, 
IHH, and HAND2 showed impaired decidualization responses leading to infertility (40, 41, 42, 
43). Chromatin immunoprecipitation coupled with high throughput sequencing (ChIP-seq) was 
performed to identify PR targets induced during decidualization (44, 45). This analysis revealed 
a role for PR in regulating the cell cycle, angiogenesis, lysosomal activity, cell death and 
apoptosis, and secretion of chemokines and cytokines, among others (44). Considerable work is 
needed to fully understand and appreciate how these PR-regulated factors work together to 
mediate decidualization. 
Progesterone receptor targets within uterine stromal cells 
The importance of functional PR signaling in the uterus is undeniable. PR is critical for 
successful pregnancy and dysregulation of PR signaling is linked to endometriosis, uterine 
fibroids, and endometrial cancer (46). ChIP-seq and gene expression analysis have identified 
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numerous PR target genes that orchestrate the molecular and biochemical changes required to 
maintain pregnancy (44, 45). Two of these factors have been highlighted below. 
 
Heart and neural crest derivatives expressed 2 (HAND2) 
PR signaling is associated with a shift from endometrial proliferation to endometrial 
differentiation. Using microarray-based profiling of progesterone responsive transcripts during 
the implantation window in the mouse identified Hand2 as a P-regulated gene in the uterine 
stroma (47). HAND2 is a basic helix-loop-helix transcription factor found in distinct tissue types, 
including the neural crest, limb buds, in the developing and adult heart, myenteric and 
submucosal sympathetic ganglia, and adrenomedullary cells (48, 49, 50). It has also emerged as a 
critical factor in the uterine stroma that regulates epithelial function (18, 43).  
HAND2 expression is induced by progesterone and is a direct target of PR (4, 18, 44, 45). 
During the peri-implantation period in mice, HAND2 expression is robustly induced in the 
stroma but is notably absent in the epithelium. Loss of HAND2 results in infertility due to a 
defect in implantation (18). Hand2 knockout mice show persistent epithelial proliferation in the 
luminal epithelium as opposed to a quiescent epithelium in control animals. As this shift to 
quiescence is requisite for implantation, this indicates that HAND2 is critical for achieving a 
receptive state in the uterus. It has been demonstrated that uterine epithelial proliferation is 
controlled in a paracrine manner by estrogen and progesterone signaling in the uterine stroma 
(10, 11). HAND2 inhibits the expression of estrogen driven stromal fibroblast growth 
factors, Fgf-1, -2, -9, and -18, which act via FGFR on the luminal epithelial cell surface and 
induce epithelial proliferation via MAPK activation (18). Additionally, loss of HAND2 leads to 
persistent epithelial ESR1 activation and increased Muc1 expression, indicative of a non-
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receptive uterine lining. Together, these findings present a mechanism by which stromal 
expression of HAND2 inhibits epithelial proliferation to promote implantation. 
The role of HAND2 during decidualization is less clear. Stromal expression of HAND2 
persists well after implantation is complete, suggesting a role of HAND2 during decidualization 
(43). HAND2 itself is a transcription factor that binds consensus ebox motifs CATCTG in the 
DNA (51). It can interact with several other transcription factors, including GATA4, TWIST1, 
and E12 to regulate gene transcription (52, 53, 54). HAND2 ChIP-seq performed in mouse heart 
and limb buds provide insights into potential HAND2 targets in the uterus (55, 56). Interestingly, 
members of the FGF family, including FGF9, appear on both data sets as targets of HAND2 
signaling. This suggests that HAND2 may directly target certain estrogen stimulated FGFs for 
transcriptional repression to promote uterine receptivity. A HAND2 ChIP-seq coupled with 
RNA-seq would be useful to help create a broader picture of target genes transcriptionally 
regulated by HAND2 during the decidualization process. 
Uterine HAND2 is also important for maintaining uterine health, as dysregulation of 
HAND2 has been linked to endometrial cancer. HAND2 is the most commonly hypermethylated 
and silenced gene in endometrial hyperplasia and cancer (57). Loss of HAND2 expression 
correlated with lack of response to progestin treatment, further supporting that HAND2 is the 
primary mediator of the anti-proliferative effects of progesterone (57). This observation also 
suggests that HAND2 status can be used to help customize a treatment regimen for women 
diagnosed with endometrial cancer. In mice, conditional deletion of uterine HAND2 led to 
complex atypical hyperplasia and downregulation of the tumor suppressor PTEN, an early event 
in the progression of endometrial carcinogenesis (57). Endometrial cancer results from chronic 
estrogen exposure, coupled with an insufficient counterbalance by progesterone, which promotes 
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the hyperproliferation and transformation of cells (46). The aim of chapter 2 is to investigate how 
exposure to endocrine disrupting chemicals with estrogenic properties, like bisphenol A, can 
alter this balance between estrogen and progesterone signaling in the uterus, and the impact on 
the PR target HAND2. 
Insulin receptor substrate 2 (IRS2) 
 IRS2 is a member of the IRS family of large docking proteins that function downstream of 
insulin and IGF1 receptor tyrosine kinases (58). IRS2 functions as an adaptor molecule bridging 
insulin (IR) and IGF-1 (IGF1R) receptor tyrosine kinases to downstream signaling proteins. 
Ligand binding induces dimerization and autophosphorylation of tyrosine residues on the 
intracellular subunits of the receptor dimers (58). The IRS2 protein contains a phosphotyrosine 
binding domain that binds the phosphorylated tyrosines on the activated receptor. This binding 
event prompts phosphorylation of multiple tyrosine residues on IRS2 by the activated receptor, 
and these residues can interact with the SH2 domains of downstream signaling proteins to 
activate PI3K/AKT and MAPK pathways. Activation of these signaling cascades regulates 
glucose influx, glycogen synthesis, and cell growth, proliferation, and differentiation (58). 
Global deletion of Irs2 results in peripheral insulin resistance and a diabetic phenotype, 
demonstrating its critical role in the insulin signaling pathway (59). Irs2 null mice also exhibit 
reduced fertility, although how IRS2 contributes to uterine function is unknown (60).  
 IRS2 acts as an adaptor molecule to IGF1R. It is well understood that estrogen-stimulated 
IGF1 produced in the uterine stroma acts on IGF1R in the uterine epithelium to mediate the 
proliferative effects of estrogen during the pre-implantation period (17, 61). However, despite 
the presence of IGF1R in the uterine stroma during the peri-implantation period, its function 
during decidualization is not well understood (62, 63). IRS2 also links insulin receptor (IR) to its 
10 
 
downstream signaling pathways. In the uterus, stromal IR expression is increased during the 
secretory phase of the uterine cycle, suggesting it plays a functional role in decidualization (64). 
In humans, insulin resistance is associated with a reduced rate of clinical pregnancies and 
increased risk of spontaneous miscarriage and recurrent pregnancy loss (65, 66, 67, 68). 
Interestingly, in vitro studies show that decidualization is reduced in the presence of added 
insulin (62, 69). In contrast, endometrial stromal cells isolated from women with polycystic 
ovarian syndrome (PCOS), a disease often associated with hyperinsulinemia and peripheral 
insulin resistance, showed impaired decidualization when differentiated in vitro (70). This 
suggests that insulin signaling is tightly regulated and perturbations can contribute to infertility. 
 IRS2 is a direct target of PR, and progesterone stimulation leads to transcriptional activation 
and increased expression (44, 45, 71). Additionally, siRNA mediated knockdown experiments 
suggest that IRS2 expression is required for decidualization in human endometrial stromal cells 
(HESC), although through what mechanism remains unclear (44). The aim of chapter 3 is to 
elucidate the mechanism by which IRS2 facilitates decidualization in primary HESC.  
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ABSTRACT 
Uterine epithelial proliferation is regulated in a paracrine manner by a complex interplay 
between estrogen (E) and progesterone (P) signaling, in which E stimulates proliferation and P 
inhibits it. Perturbation of steroid hormone signaling within the uterine milieu could contribute to 
the development of endometrial hyperplasia and cancer. It is well established that bisphenol-A 
(BPA) is an endocrine disrupting chemical with weak estrogenic effects, although little is known 
about how it affects steroid hormone signaling in the adult uterus. Because BPA acts as a weak 
E, we hypothesized that chronic exposure to BPA would create an imbalance between E and P 
signaling and cause changes in the uterus, such as aberrant epithelial proliferation. Indeed, 
exposure to an environmentally relevant dose of BPA had a uterotrophic affect. BPA-treated 
mice showed increased proliferation, notably in the glandular epithelium, which is a site of origin 
for endometrial hyperplasia and cancer. Increased proliferation appeared to be mediated through 
a similar mechanism as E-induced proliferation, via activation of the fibroblast growth factor 
receptor pathway and phosphorylation of the ERK1/2 mitogen-activated protein kinases in the 
epithelium. Interestingly, BPA reduced expression of heart and neural crest derivatives expressed 
2 (HAND2), a known mediator of the anti-proliferative effects of P. BPA also increased 
methylation of a CpG island in the Hand2 gene promoter, suggesting that BPA may promote 
epithelial proliferation through epigenetic silencing of anti-proliferative factors like HAND2. 
Collectively, these findings establish that chronic exposure to BPA impairs steroid hormone 
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signaling in the mouse uterus and may contribute to the pathogenesis of uterine hyperplasia and 
cancer.  
INTRODUCTION 
The endometrium is highly sensitive to stimulation by ovarian steroid hormones estrogen (E) 
and progesterone (P). These two hormones play critical roles both during the reproductive cycle 
and pregnancy to maintain normal uterine health. An imbalance in E and P signaling can lead to 
loss of pregnancy and a number of uterine pathologies, including endometrial hyperplasia and 
cancer. One of the physiological functions regulated by E and P is proliferation of the uterine 
epithelium. It is well established that E drives epithelial proliferation and P inhibits proliferation 
(1, 2). In the presence of E, uterine stromal cells produce a subset of fibroblast growth factors 
(FGFs) that act in a paracrine manner to activate FGF receptor (FGFR) signaling in the uterine 
epithelium, leading to subsequent proliferation through MAPK activation (3). When P is present, 
activation of its cognate receptor in the uterine stromal cells drives expression of heart and neural 
crest derivatives expressed 2 (HAND2), which inhibits the expression of these FGFs and acts as 
a mediator of the anti-proliferative actions of P (3). When HAND2 is lost from the uterus 
through conditional deletion, FGF levels remain elevated and uterine epithelial proliferation 
persists. 
Unchecked endometrial proliferation is a common feature of endometrial hyperplasia and 
leads to an increased risk of endometrial cancer. Worldwide, endometrial cancer is the most 
common gynecological cancer, with an estimated 287,000 new cases developing annually (4). 
The majority of endometrial carcinomas are classified as endometrioid endometrial 
adenocarcinomas and originate in the epithelium lining the uterine glands (5). Women who are 
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nulliparous, obese, diabetic, or experiencing prolonged/unopposed exposure to E face an 
increased risk of developing endometrial cancer (5). Endometrial carcinomas are preceded by 
endometrial hyperplasia, a precursor lesion associated with abnormal proliferation. Endometrial 
hyperplasia results from chronic E exposure, coupled with an insufficient counterbalance by P, 
which promotes the hyperproliferation and transformation of cells (6). The findings of the 
Postmenopausal Estrogen/Progestin Interventions trial support these observations, showing that 
administration of E-only hormone replacement therapy increased incidence of endometrial 
hyperplasia, whereas administration of E+P showed rates of hyperplasia similar to placebo (7). 
Moreover, findings from the Women’s Health Initiative show that combined E+P therapy in 
postmenopausal women decreased incidence of endometrial cancer compared with placebo (8). 
The findings of these trials highlight the importance of maintaining a proper balance of E and P 
for uterine health. 
Endometrial hyperplasia is characterized by abnormal glandular proliferation resulting in 
an increase in the gland:stroma ratio and glandular remodeling, resulting in irregularities in gland 
shape and distribution throughout the endometrium (5, 9). Progestin therapy has been shown to 
be effective at regressing endometrial hyperplasia, demonstrating the importance of P as an anti-
proliferative agent (10). These observations highlight the importance of maintaining a balance of 
pro-proliferative E and anti-proliferative P signaling in the uterus to maintain normal uterine 
health and function. Thus, it is important to determine if exposure to endocrine disrupting 




Endocrine disruptors are both natural and manmade substances that interfere with or 
inhibit the body’s normal endocrine function by mimicking endogenous hormones, interacting 
with the hormones’ cognate receptor, and/or altering endogenous hormone synthesis. Perhaps 
one of the most pervasive endocrine disrupting chemicals is bisphenol-A (BPA), a component of 
polycarbonate plastics found in plastic food and drink containers, epoxy resins lining food cans, 
and thermal paper (11). Elevated serum or urine levels of BPA have been associated with several 
endocrine related diseases, including obesity, diabetes, polycystic ovarian syndrome, and thyroid 
dysfunction (12–15). Although it possesses a lower binding affinity to the estrogen receptor (ER) 
than estradiol itself, BPA has been shown to exhibit estrogenic effects (16–19). Because the 
uterus is highly sensitive to E stimulation, it is possible that estrogenic compounds such as BPA 
may adversely affect E-regulated processes involved in normal uterine cyclicity and pregnancy. 
In rodent models, BPA has been shown to affect several reproductive parameters, 
including increased GnRH pulse frequency, reduced LH secretion, premature onset of puberty, 
and abnormal estrus cycle (20). Several animal studies have also demonstrated reduced fertility 
stemming from delayed embryo implantation and a decreased number of implantation sites in 
rodents exposed to BPA (21–24). Other studies have proposed a transgenerational effect of BPA 
on fertility, wherein pregnant dams dosed with BPA give rise to filial generations 1–3 exhibiting 
reduced fertility, including reduced number of pregnancies and reduced number of pregnancies 
carried to term (25, 26). These observations suggest BPA exposure in the mother causes changes 
in the daughters and granddaughters through an epigenetic mechanism. In women, elevated 
levels of BPA in serum or urine have been associated with lower antral follicle counts, 
implantation failure, and increased risk of miscarriage (27–29). It is clear based on the rodent 
studies and the human epidemiological studies that reproductive tissues are acutely sensitive to 
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the endocrine disrupting chemical BPA, and basic physiological processes, such as reproduction, 
are highly susceptible to BPA exposure. 
Many studies have focused on the effects of BPA exposure during critical windows of 
development, such as during the perinatal period or during puberty, but relatively little is known 
about the consequences of BPA exposure during adulthood. Based on the endocrine disrupting 
nature of BPA, we hypothesized that BPA exposure would disrupt the balance of steroid 
hormone signaling in the adult uterus and lead to dysregulation of the molecular pathway 
controlling endometrial proliferation. We used an experimental model wherein reproductively 
mature cycling female mice were exposed for long durations to a concentration of BPA 
comparable to the level established by the US Environmental Protection Agency (EPA) as the 
safe level for human exposure. Moreover, we used oral administration to better mimic the route 
of human exposure to BPA. We found that chronic exposure to BPA induces uterine glandular 
proliferation through suppression of HAND2, a known mediator of the anti-proliferative effects 
of P. 
MATERIALS AND METHODS 
Animals and experimental protocol 
C57BL6 mice were maintained in a University of Illinois–sponsored animal care facility 
and all procedures were approved by the University of Illinois Institutional Animal Care and Use 
Committee. Mice were housed in polysulfone cages containing corn cob bedding and fed Teklad 
8664 rodent chow (Envigo) ad libitum. Water was provided ad libitum in glass bottles. For 
dosing experiments, reproductively mature (8-week-old) intact female mice were treated three 
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times per day (9:00 AM, 1:00 PM, and 5:00 PM) orally with BPA [60 µg/kg/d, cumulative, 
dissolved in ethanol, and suspended in tocopherol-stripped corn oil for 0.1% final ethanol 
concentration (Sigma)] or vehicle (tocopherol-stripped corn oil + 0.1% ethanol). Mice were fed 
these solutions by pipette and treatment continued for 60 days. At the end of the dosing period, 
vaginal cytology was used to determine stage of estrus, and animals were euthanized as they 
entered diestrus. Upon euthanization, uteri were collected, weighed, divided, and either fixed in 
10% buffered formalin or flash frozen in liquid nitrogen for further analysis. 
Immunohistochemistry 
Formalin-fixed uterine segments were paraffin embedded and cross-sectioned to 5 µM 
thickness onto glass slides. Before staining, slides were deparaffinized in xylene and rehydrated 
in ethanol. Slides to be developed with chromagen were incubated in 0.3% hydrogen peroxide in 
methanol for 15 minutes at room temperature to quench endogenous peroxidase activity. Slides 
were subjected to antigen retrieval, blocked with normal donkey serum, and incubated overnight 
at 4°C with primary antibody diluted in immunohistochemistry block A solution (0.25% BSA, 
0.3% Triton X-100, sterile PBS). Primary antibodies used are as follows: cytokeratin 8 
(Hybridoma Bank; RRID: AB_531826) (30), Ki67 (BD Pharmingen; RRID: AB_393778) (31), 
phosphorylated FGFR substrate 2 (FRS2; R&D Systems; RRID: AB_2106234) (32), 
phosphorylated ERK1/2 (Santa Cruz; RRID: AB_653182) (33), PR (Dako; RRID: AB_2315192) 
(34), and HAND2 (Santa Cruz; RRID: AB_2115995) (35). The next day, slides were washed in 
PBS and incubated with either biotinylated or Cy3/Dylite conjugated secondary antibody 
(Jackson Immunoresearch Laboratories, Inc.; RRID: AB_2340788, RRID: AB_2340398, 
RRID: AB_2315777, RRID: AB_2307443, and RRID: AB_2340616) (36–40) diluted in PBS 
and 1% BSA for 1 hour at room temperature. Immunofluorescence stained slides were washed 
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and mounted with Prolong GOLD mounting medium (Promega) containing 4′,6-diamidino-2-
phenylindole (DAPI). Biotinylated samples were incubated with streptavidin conjugated 
horseradish peroxidase (Invitrogen) for 30 minutes at room temperature. Samples were then 
stained with 3-amino-9-ethyl carbazole solution (Invitrogen) and counterstained with Mayer 
hematoxylin (Sigma). Slides were mounted with organic mounting medium before imaging. 
Imaging was performed using a Leica DM2500 light microscope (Leica Microsystems) fitted 
with a Qimaging Retiga 2000R camera (Teledyne Qimaging). Immunofluorescent images were 
captured on an Olympus BX51 fluorescence microscope (Olympus) fitted with an Olympus 
DP71 camera (Olympus). ImageJ software (National Institutes of Health) was used to perform 
post-imaging analysis. 
Uterine stromal cell isolation 
Uteri were isolated from intact, reproductively mature mice in diestrus, as determined by 
vaginal cytology. Uterine horns were cut open longitudinally and divided into 3 mm pieces. This 
tissue was incubated in a solution of Hanks buffered salt solution (HBSS) containing 25 g/L of 
pancreatin (Sigma-Aldrich) and 6 g/L of dispase (Gibco) at room temperature for 1 hour and 
then 37°C for 15 minutes. The tissue was then washed with HBSS supplemented with 10% FBS 
and then HBSS alone. Tissue was then incubated in HBSS containing 0.5 g/L of collagenase 
(Gibco) for 1 hour at 37°C. HBSS containing 10% FBS was added to stop digestion; stromal 
cells were dissociated by pipetting. Cell suspensions were then passed through a 70 µm mesh 
cell strainer (VWR) to remove tissue debris. Stromal cells were plated in DMEM/F12 culture 
media (Gibco) containing 2% charcoal–stripped calf serum (Gibco) and treated with 5 µM of 
BPA or ethanol as vehicle for 48 hours. In a subset of experiments, cells were plated and treated 
with 5 µM of BPA in the presence or absence of 10 µM ICI 182,780 (Sigma) for 48 hours. In 
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another subset of experiments, cells were plated and treated with ethanol vehicle or 10 µM S-
adenosylmethionine (SAM; New England Biolabs) for 24 hours. To induce Hand2 expression, 1 
µM of P (Sigma) was added to the treatment and cells were cultured for an additional 12 hours. 
Cells were then washed in PBS and harvested in TRIZOL for further RNA isolation and gene 
expression analysis. 
RNA isolation and real-time qPCR analysis 
Frozen uteri were homogenized and RNA isolated using TRIZOL reagent (Life 
Technologies), according to the manufacturer's protocol. cDNA was prepared using the 
AffinityScript Multiple Temperature Reverse transcription, according to the manufacturer’s 
protocol (Agilent Technologies). The cDNA was amplified to quantify gene expression by real-
time PCR, using gene specific primers and Power SYBR Green PCR Master Mix (Applied 
Biosystems). The expression level of 36b4 was used as the internal control. For each treatment, 
the mean cycle threshold (Ct) and SD were calculated from individual Ct values obtained from 
three replicates of a sample. The normalized ΔCt in each sample was calculated as mean Ct of 
target gene subtracted by the mean Ct of internal control gene. ΔΔCt was then calculated as the 
difference between the ΔCt values of the vehicle and BPA treatment samples. The fold change of 
gene expression in each sample relative to a control was computed as 2
−ΔΔCt
. The mean fold 
induction and SEs were calculated from four independent experiments. 
Methylation analysis 
Methylation status was assessed using the EpiTect Methyl II PCR Assay (Qiagen). 
Briefly, genomic DNA was isolated from uteri of vehicle and BPA-treated mice using the 
DNeasy Blood and Tissue Kit (Qiagen), according to the manufacturer’s protocol. In a subset of 
methylation analysis experiments, DNA was isolated from primary murine uterine stromal cells 
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that were treated with ethanol vehicle or SAM for 24 hours and then cotreated with P for 12 
hours. Enzymatic treatment with the methyltransferase SssI and the methyl donor S-Adenosyl 
Methionine (New England Biolabs) was used to generate hypermethylated DNA as a positive 
control. Genomic DNA was then subjected to methyl-sensitive and methyl-dependent restriction 
enzyme digestion using the EpiTect II DNA Methylation Enzyme Kit (Qiagen). Methylation 
status of the isolated genomic DNA was assayed using the EpiTect Methyl II PCR Assay 
(Qiagen) with primer sets targeting two CpG islands in the mouse Hand2 gene. Ct values 
obtained from the different restriction enzyme conditions were used to calculate the percentage 
of methylated and unmethylated input DNA, as described in the manufacturer’s protocol. The 
mean percentage of methylated input DNA and SEs were calculated from four independent 
experiments. 
Statistical Analysis 
Statistical significance between control and BPA-treated samples/tissues was determined 
using the Student t test. Asterisks denote significance with a P value <0.05. 
 
RESULTS 
Chronic BPA treatment is uterotrophic and increases the gland:stroma ratio 
To assess the risks of long-term exposure to the endocrine disruptor BPA in the uterus, 
we exposed reproductively mature cycling female mice three times a day orally to a cumulative 
dose of 60 µg/kg/d of BPA for 60 days. This concentration was chosen to reflect the reference 
dose established by the EPA and represents an estimate of the daily exposure likely to be without 
appreciable risk of deleterious effects (41). Oral route of administration was used to recapitulate 
the route of exposure in human populations. Uterine weight was measured upon euthanization, 
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normalized to body weight, and expressed as fold change compared to vehicle [Fig. 2.1(a)]. A 
substantial increase in uterine wet weight was observed following long-term exposure to BPA 
compared with uteri from vehicle (corn oil only)-treated animals, indicating that chronic 
exposure to BPA has a uterotrophic effect. We next used hematoxylin and eosin staining to look 
at general uterine morphology [Fig. 2.1(b)]. Uteri from BPA-treated animals appeared to have an 
increased number of uterine glands dispersed throughout the endometrium compared with 
vehicle-treated animals. To further investigate this observation, we subjected uterine sections to 
immunohistochemistry using cytokeratin 8 as an epithelial marker. Cytokeratin positive 
structures were counted and expressed relative to stromal area, as determined by ImageJ 
(National Institutes of Health). We found that exposure to BPA increased the uterine 
gland:stroma ratio compared with the vehicle as a control [Fig. 2.1(c)]. Because increased 
gland:stroma ratios are often observed in incidences of hyperplasia, we further investigated into 
uterine abnormalities following BPA exposure. 
Changes in proliferation and glandular morphology following chronic BPA exposure 
To determine if long-term exposure to BPA alters epithelial proliferation, we subjected 
uterine sections to immunohistochemistry using Ki67 as a marker for proliferation [Fig. 2.2(a)]. 
Indeed, we observed that uteri from mice exposed to BPA showed increased levels of 
proliferation, as indicated by Ki67
+
 staining in brown. The staining was particularly pronounced 
in the luminal epithelium and the uterine glands of BPA-exposed animals compared with the 
vehicle-treated controls. Because aberrant proliferative activity in glandular epithelium is one of 
the hallmarks of endometrial hyperplasia, we further looked at the glandular morphology in uteri 
of vehicle and BPA-treated animals using cytokeratin 8 [Fig. 2.2(b)]. Uteri of BPA-exposed 
animals exhibited densely packed clusters of glands, as well as elongated, irregularly shaped 
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glands, compared with smaller, rounder, more evenly distributed glands found in uteri of vehicle-
treated mice. These changes in proliferation, glandular architecture, and the gland:stroma ratio 
suggest that long-term BPA exposure may give rise to endometrial hyperplasia. We next 
determined the mechanism by which BPA alters endometrial proliferation. 
BPA alters expression of the PR target HAND2 
It is well established that endometrial proliferation is influenced by a balance of pro-
proliferative E and anti-proliferative P signaling. Because we observed an increase in glandular 
proliferation following BPA exposure, we next wanted to investigate whether aspects of P 
signaling were impaired. We looked at expression of the progesterone receptor (PR) target 
HAND2, a stromal factor that has been shown to mediate the anti-proliferative effects of P (3). 
Gene expression analysis revealed that uterine Hand2 expression is reduced following chronic 
BPA exposure compared with vehicle-treated animals [Fig. 2.3(a)]. In addition, HAND2 protein 
is robustly expressed in the subepithelial stroma of mice treated with vehicle, as indicated by 
immunohistochemistry [Fig. 2.3(b)]. In BPA-treated animals, HAND2 is also detected in the 
subepithelial stroma, but to a lesser extent than in vehicle-treated animals. Indeed, when we 
quantify the number of HAND2
+ 
stromal cells using ImageJ software, we see a substantial 
decrease in the number of HAND2
+
 cells in the subepithelial stromal compartment of BPA-
treated mice, compared with vehicle [Fig. 2.3(b)]. This indicates that BPA exposure leads to 
downregulation of the downstream mediator of PR, resulting in persistent epithelial proliferation. 
We next determined whether PR expression itself is impaired in response to BPA 
exposure by using quantitative PCR (qPCR) [Fig. 2.3(c)]. Compared with vehicle, BPA-treated 
animals showed slightly higher expression of PR, although this was not statistically significant. 
Consistent with this RNA profile, we found that PR expression is maintained both in the 
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epithelium and the stroma following BPA exposure [Fig. 2.3(d)]. These data suggest that reduced 
HAND2 expression following BPA exposure is due to changes in PR transcriptional activity 
rather than reduced PR expression. 
Chronic BPA exposure alters FGF signaling in the glandular epithelium 
Previously, we have shown that a primary function of HAND2 is to regulate uterine 
epithelial proliferation by suppressing expression of paracrine acting FGFs in the uterine stroma 
(3). We next determined the consequences of BPA exposure on FGF levels by performing qPCR 
using uterine samples obtained from our BPA- or vehicle-exposed mice. We found that mice 
chronically exposed to BPA exhibited significantly increased uterine expression 
of Fgf9 and Fgf18 compared with vehicle-treated animals [Fig. 2.4(a)], indicating that reduced 
HAND2 expression corresponds with increased FGF production. 
FGFs signal through membrane bound FGFR. Binding of the ligand to the receptor 
triggers receptor activation and subsequent phosphorylation of FRS2. Using this phosphorylation 
event as a readout of FGFR activation, we performed immunohistochemistry using an antibody 
specific for phosphorylated FRS2 (pFRS2) [Fig. 2.4(b)]. We found that FGFR activation was 
greatly increased in the glandular epithelium following chronic BPA exposure compared with 
vehicle-treated animals, as indicated by pFRS2 staining in red. FGFR activation can lead to 
increased proliferation, which is mediated through activation of the MAPK cascade. Indeed, we 
have previously shown that loss of MAPK activation can attenuate proliferation in the uterine 
epithelium (3). To determine if BPA exposure leads to increased MAPK activation, we 
performed immunohistochemistry using an antibody specific to phosphorylated ERK1/2 [Fig. 
2.4(b)]. We found that phosphorylation and activation of ERK1/2 was robustly increased in the 
uterine glands of animals exposed to BPA compared with vehicle-treated animals, as indicated 
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by pERK1/2 staining in green. Together, these data establish a mechanism whereby BPA induces 
expression of FGFs that bind FGFR in the glandular epithelium, leading to downstream MAPK 
activation and increased proliferation. 
To further investigate how BPA modulates Fgf9 and Fgf18 expression in the uterus, we 
used an in vitro system in which stromal cells were isolated from the uterus and placed into 
culture. These cells were then stimulated with 5 µM of BPA for 48 hours; the resulting RNA was 
subjected to gene expression analysis using primers specific to Fgf9 and Fgf18. Indeed, cells 
exposed to BPA showed increased expression of Fgf9 and Fgf18 compared with vehicle-treated 
cells [Fig. 2.5(a)], indicating that BPA can drive expression of paracrine acting FGFs in stromal 
cells. These observations are in agreement with those seen in vivo [Fig. 2.4(a)]. We next 
investigated the nature of this regulation and the involvement of ER. Previous groups have 
shown that FGF expression is positively regulated by E (42, 43). To determine if BPA is 
promoting FGF production through ER, we treated uterine stromal cells in vitro with BPA in the 
presence or absence of ER antagonist ICI 182,780 [Fig. 2.5(b)]. We observe marked reduction in 
BPA stimulated Fgf9 and Fgf18levels with inclusion of ICI 182,780, indicating that functional 
ER is required for BPA-mediated induction of FGFs. 
BPA induces differential methylation at the Hand2 promoter and increased expression of 
methylation related factors 
Chronic BPA exposure reduces HAND2 expression, but does not alter the expression of 
PR, the upstream regulator of HAND2. This suggests that BPA may be interfering with the 
ability of PR to recognize and stably bind to its downstream targets as opposed to decreasing the 
levels of PR available to signal. Previous studies have shown that BPA exposure causes 
differential methylation of certain gene promoters, which can lead to changes in gene expression 
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from the affected promoters (44–47). To determine if BPA downregulates HAND2 in the uterus 
via hypermethylation and gene silencing, we looked at the methylation status of 
the Hand2 promoter following chronic BPA exposure [Fig. 2.6(a)]. Our analysis focused on 
methylation within two different CpG islands proximal to the Hand2 transcription start site [Fig. 
2.6(a)]. We observed a substantial increase in DNA methylation in uterine samples following 
chronic BPA exposure at the first CpG island assayed, flanking the Hand2transcription start site. 
No differential methylation was observed in the second CpG island, coding for the 5′-UTR and 
exon1 of Hand2. MatInspector software by Genomatix was used to identify transcription factor 
binding sites within this first CpG island. We identified several potential transcription factor 
binding sites within this region, including response elements for Kruppel-like factors, signal 
transducer and activator of transcription, GATA binding proteins, and hypoxia inducible factors. 
Further investigation is needed to determine what regulatory elements in this region may be 
required for proper Hand2 expression. 
We next used our in vitro system to further investigate the link between methylation at 
the Hand2 promoter and how this affects its expression. SAM is a methyl donor that supplies 
DNA methyltransferases with the methyl group for transfer to cytosine residues in DNA. We 
exposed uterine stromal cells to 10 μM of the methyl donor SAM and then 
stimulated Hand2 expression with P. We observed increased DNA methylation at the CpG island 
110765 flanking the Hand2 transcription start site following treatment with P and SAM, 
compared with vehicle or P alone [Fig. 2.6(b)]. We saw no change in DNA methylation at CpG 
island 110766, consistent with our in vivo observations [Fig. 2.6(a)]. We next analyzed gene 
expression changes and observed increased Hand2 expression following stimulation with P. This 
induction was blocked by treatment with SAM [Fig. 2.6(c)]. Moreover, expression of a DNA 
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methyltransferase, Dnmt3b, is unchanged, indicating that reduced gene expression in response to 
SAM is not a global effect. Together, these in vitro data suggest that increased methylation at 
the Hand2 promoter can impair HAND2 expression. 
DNA methylation and gene silencing are mediated by DNA methyltransferases and 
methylated DNA binding proteins. A growing body of literature suggests that BPA exposure 
modulates expression of these factors in a variety of tissue types (44–47). We observed increased 
uterine expression of several of these factors, including DNA 
methyltransferases Dnmt1 and Dnmt3b and methylated DNA binding protein Mbd2, in vivo 
following chronic oral exposure to BPA [Fig. 2.7(a)]. We also observed 
increased Dnmt1, Dnmt3b, and Mbd2 expression in primary uterine stromal cells treated with 
BPA in vitro [Fig. 2.7(b)]. Previous studies have shown Dnmt expression is induced by E acting 
through ER (48, 49). Inclusion of the ER antagonist ICI 182,780 to BPA-treated uterine stromal 
cells in vitro reduces the expression of Dnmt1 and Dnmt3b, compared with BPA alone, 
suggesting that BPA acts via ER to upregulate Dnmt expression [Fig. 2.7(c)]. 
Based on these data, we propose a mechanism by which BPA exposure induces 
methylation at the Hand2 promoter, which obstructs transcription factor binding and recruitment 
of transcription machinery and decreases Hand2 expression. Reduced expression of HAND2 
alleviates antagonism of FGF production, allowing for increased FGF stimulation of the uterine 
glandular epithelium and subsequent proliferation [Fig. 2.8]. 
 
DISCUSSION 
BPA exposure in the general population is ubiquitous, and numerous biomonitoring 
studies have shown measurable BPA levels in serum and urine of children and adults all over the 
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world (11). These observations highlight the importance of understanding the adverse health 
effects associated with BPA exposure. A recent study demonstrated that a single oral exposure to 
50 μg/kg led to BPA accumulation in the uteri of both cycling and pregnant rats and mice within 
an hour of exposure (50). Moreover, ∼72% of the BPA recovered from uterine samples was in 
the aglycone form, which is capable of interacting with steroid receptors. In this study, we report 
that BPA has uterotrophic effects in the cycling mouse uterus [Fig. 2.1(a)]. This uterotrophic 
effect is consistent with observations made by other groups (51, 52). However, these studies used 
doses delivered via injection or continuous exposure via ALZET pump for short treatment 
periods and may not adequately represent the common oral route of exposure in humans. In the 
current study, we demonstrate that oral exposure to a lower concentration of BPA for a longer 
treatment period can also induce a uterotrophic response. Currently, the reference dose for BPA 
is 50 µg/kg/d, as established by the EPA. This represents an estimate of the daily exposure in 
humans likely to be without appreciable risk of deleterious effects. Our study establishes that 
BPA exposure comparable to what the EPA deems safe for human exposure can lead to 
undesirable uterine pathologies in mice. 
Aberrant proliferation is a hallmark of hyperplasia, a condition characterized by an 
increase in cell number without changes to cell morphology. Hyperplasia is not cancer, but a pre-
neoplastic lesion that can develop into cancer with further genetic mutations or environmental 
insults to the epigenome. Here we report that BPA exposure leads to aberrant proliferation of the 
uterine epithelium, as indicated by Ki67 staining [Fig. 2.2(a)]. Notably, proliferation was 
particularly robust in the epithelium of the uterine glands, which are the predominant site of 
origin for endometrial hyperplasia. A previous study demonstrated that gestational exposure to 
low doses of BPA (ng/kg/d) led to increased 5-bromo-2′-deoxyuridine incorporation and DNA 
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synthesis in the glandular epithelium of pups at 3 months of age (53). These findings support the 
observations made in this study; however, because a different dosing paradigm and age of 
exposure was used, different mechanisms may be at play compared with the current study. In 
addition to increased proliferation, we observed changes in uterine glandular architecture which 
are consistent with endometrial hyperplasia, including increased gland:stroma ratio [Fig. 2.1(c)], 
densely clustered glands, and enlarged, irregularly shaped glands [Fig. 2.2(b)]. Several rodent 
studies have shown that BPA exposure during the perinatal period increased incidence of uterine 
gland abnormalities later in life, including signs of cystic hyperplasia and squamous metaplasia 
(54, 55). Again, these data are consistent with our observations; however, our study also 
demonstrates that BPA exposure outside of the critical windows of development can have 
deleterious effects in the uterine glands, perhaps through an alternative mechanism. Another 
study reported changes in uterine architecture following BPA exposure in adults, including 
increased epithelial height and increased stromal and myometrial thickness (56). However, this 
study dosed mice acutely (4 days) and does not provide insight into the effects of chronic BPA 
exposure. Interestingly, Hiroi et al. examined serum BPA levels in women with endometrial 
hyperplasia and showed that BPA levels were reduced in patients with complex endometrial 
hyperplasia and endometrial cancer compared with healthy patients (57). The authors 
hypothesize that the reduced BPA levels may be a result of altered metabolism of BPA or that 
BPA exerts anti-estrogenic effects. Endocrine disrupting chemicals such as BPA have been 
shown to exhibit nonmonotonic dose responses, meaning that the dose response curve generated 
for a specific response resembles a “U” shape, showing a greater magnitude of response at lower 
and higher doses, and a lesser magnitude of response at intermediate doses (58). In light of this, 
perhaps the lower concentrations observed in women with endometrial hyperplasia and cancer 
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correspond with a greater response (i.e., hyperplasia compared with healthy patients with higher 
serum BPA levels). 
We report here that BPA causes aberrant Fgf production and FGFR activation in uterine 
tissue. The FGF family consists of 18 secreted proteins that serve as ligands to 4 membrane 
bound tyrosine kinase receptors (59). FGFs bind to membrane bound FGFRs and trigger receptor 
dimerization, activation, and autophosphorylation that recruits the adaptor protein FRS2. FRS2 is 
phosphorylated on several tyrosine residues that serve as docking sites for downstream signaling 
molecules that lead to activation of the MAPK pathway and the phosphatidylinositol 3-
kinase/AKT pathway. FGF signaling orchestrates multiple biological responses, including cell 
proliferation, cell migration, and angiogenesis (60). In the uterus, FGFs produced in the stroma 
act in a paracrine fashion to induce proliferation of epithelial cells (3). In a previous study, using 
a delayed implantation model, we observed that pre-pubertal exposure to BPA leads to impaired 
implantation (24). This is accompanied by increased stromal FGF production, increased 
epithelial FGFR activation and MAPK activity, and persistent proliferation in the luminal 
epithelium that renders it unreceptive to blastocyst implantation. Similar to what is observed in 
the pregnant mouse uterus, here we show BPA increases Fgf production [Fig. 2.4(a) and 2.5(a)] 
and leads to FGFR activation and increased MAPK activity in the adult non-pregnant uterine 
glands, as indicated by pFRS2 and pERK1/2 staining [Fig. 2.4(b)]. Aberrant activation of this 
signaling pathway is likely a driver for epithelial proliferation, increased gland:stroma ratio, and 
changes in glandular morphology observed in BPA-treated mice. Aberrant FGF signaling has 
been previously observed in human endometrial cancer, where activating mutations in FGFR2 
have been reported in 10% to 12% of primary uterine tumors (61, 62). Inhibition of FGFR2 
expression or activity both resulted in decreased endometrial tumor cell survival and 
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transformation, indicating that excessive FGFR2 activation contributes to endometrial cancer 
progression (62). Pharmacological agents targeting FGF signaling are currently being explored 
for use in the treatment of endometrial cancers (63). Here, we show that BPA exposure leads to a 
robust increase in Fgf9 expression and corresponding activation of FGFR in the glandular 
epithelium. FGF9 has a greater binding affinity for FGFR2 and FGFR3 than FGFR1 and 4 (64). 
We hypothesize that increased production of FGF9 in response to BPA exposure acts on FGFR2 
in the glandular epithelial cells to promote proliferation. Further experiments are needed to 
determine which FGFR isoform is responsible for mediating the proliferative effects of FGF9 in 
the uterine glands. 
In the current study, we show that chronic exposure to BPA increases methylation of a 
CpG island in the murine Hand2 promoter and correlates with reduced uterine Hand2 transcript 
levels compared with vehicle-treated animals [Fig. 2.6(a) and 2.3(a)]. This linkage between 
methylation at the Hand2 promoter and reduced Hand2 expression was also observed in 
vitro using the methyl donor SAM [Fig. 2.6(b-c)]. CpG islands represent short stretches of DNA 
that are rich in CpG dinucleotides. Many of these areas are associated with gene promoters, and 
CpGs in these regions are generally protected from methylation. In the incidence of cancer, 
global methylation analysis reveals that cancer genome in tissues such as breast, colon, and 
prostate tend to be hypomethylated in the intergenic and intronic regions relative to normal 
healthy tissue, whereas specific CpG islands tend to be concurrently hypermethylated with the 
incidence of cancer (65, 66). Other groups have shown that CpGs located within promoters of 
genes associated with tumor suppression, DNA repair, and hormone receptors are 
hypermethylated in tumor samples and cancer cell lines, and that demethylation of these regions 
with 5-aza-2′-deoxycytidine could restore gene expression (67–69). There is a growing body of 
35 
 
literature suggesting that BPA modifies gene expression through an epigenetic mechanism, 
including modulating CpG methylation at target gene promoters and regulatory regions that 
correlates with reduced gene expression (44–47, 70). A number of studies also show that 
exposure to BPA increases the expression of DNA methyltransferases in various tissues such as 
heart, liver, and testis, and suggest this may be a mechanism by which BPA mediates 
hypermethylation and gene silencing (44–47). Similarly, in our study in the uterus, we observed 
that BPA induces increased mRNA expression of Dnmt1, a maintenance methylase, Dnmt3b, 
a de novo methylase, as well as increased expression of Mbd2, a protein that binds methylated 
DNA and mediates transcriptional repression at methylated gene promoters [Fig. 2.7(a)]. We 
have further shown that, in regard to Dnmt1 and Dnmt3b, this action is mediated through ER 
[Fig. 2.7(c)]. It is possible that elevated expression levels of these factors may be mediating the 
hypermethylation and transcriptional repression of Hand2 in the uterus of BPA-treated mice. 
Interestingly, we see that uterine PR expression appears to be unchanged between 
vehicle- and BPA-treated mice [Fig. 2.3(c-d)]. This is in contrast to our previous study showing 
the effects of BPA exposure during pregnancy, in which BPA reduced not only HAND2, but also 
PR expression (24). P, through the activation of PR, induces HAND2 expression in the uterine 
stroma. This suggests that during pregnancy, the reduction in HAND2 expression in response to 
BPA is due to reduced levels of PR. In the current study, our data indicate that in the non-
pregnant uterus BPA is interfering with PR transcriptional activity by inhibiting its ability to 
interact with the target gene rather than through inhibition of PR expression itself. 
HAND2 is a critical mediator of the anti-proliferative effects of P in the uterus (3). We 
have previously observed that BPA reduces HAND2 expression during early pregnancy (24). A 
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pervasive consequence of HAND2 loss is persistent epithelial proliferation, which would suggest 
that HAND2 may play a role in preventing uterine hyperplasia and cancer. Indeed, mice lacking 
uterine HAND2 exhibit signs of complex atypical hyperplasia in their uterine glands, including 
changes in glandular morphology and an increase in the gland:stoma ratio, compared with their 
age-matched controls (71). In humans, we have shown that HAND2 is the most commonly 
hypermethylated and silenced gene in endometrial cancer (71). 
Moreover, HAND2 hypermethylation and silencing is observed in endometrial precancerous 
lesions, indicating that loss of HAND2 occurs early on in the progression of endometrial cancer. 
Interestingly, HAND2 hypermethylation correlates with failure to respond to P therapies to treat 
endometrial cancer, indicating that HAND2 is the primary mediator of the anti-proliferative 
effects of P. With chronic BPA treatment in non-pregnant adult mice, we observed decreased 
HAND2 expression and increased glandular proliferation, suggesting that the repression of 
HAND2 plays a critical role in driving the hyperplastic effects of BPA in the uterus. 
CONCLUSION 
Our studies demonstrate that chronic oral exposure to a low concentration of BPA during 
adulthood impedes transcriptional activation of the anti-proliferative factor HAND2, likely 
through an epigenetic mechanism involving hypermethylation at the Hand2 promoter. Reduction 
of HAND2 alleviates its repression of FGFs, increasing FGF levels and promoting FGF-induced 
epithelial proliferation in the uterine glands and altered glandular morphology. This is mediated 
through increased MAPK activity downstream of glandular FGFR activation. This study offers 
further insight into the endocrine disrupting nature of BPA and provides a potential mechanism 









Figure 2.1 Chronic BPA treatment increases uterine weight and increases the gland:stroma 
ratio 
(a) Reproductively mature female mice (8 wk of age) were treated three times per day with 
vehicle (corn oil) or BPA (cumulative dose of 60 µg/kg/d in corn oil) for 60 d. Animals were 
euthanized in diestrus, as determined by vaginal cytology. Uterine wet weight was measured on 
collection. Weights were normalized to animal body weight, and data are represented as the 
mean fold change ± SEM; *P < 0.05. (b) Representative hematoxylin and eosin staining of 
uterine sections obtained from vehicle- and BPA-treated mice. (Magnification, ×10). (c) Uterine 
sections were subjected to immunohistochemistry and stained with cytokeratin 8 as an epithelial 
marker. Glands were counted and expressed relative to stromal area using ImageJ software. Data 






Figure 2.2 Changes in proliferation and glandular morphology following chronic BPA 
exposure 
(a) Uterine sections obtained from vehicle- and BPA-treated (60 µg/kg/d for 60 d) mice were 
subjected to immunohistochemistry using Ki67 to indicate proliferating cells. Brown staining 
indicates Ki67
+
 cells. Arrows highlight actively proliferating uterine glands. [Magnification, ×20 
(top), ×40 (bottom).] (b) Cytokeratin 8 (red) staining of uterine sections obtained from vehicle- 
and BPA-treated mice. DAPI was used as a nuclear counterstain. (Magnification, ×20.) G, 











Figure 2.3 continued: (a) RNA isolated from vehicle- and BPA-treated (60 µg/kg/d for 60 d) 
mice was subjected to qPCR using primers specific to Hand2. 36b4 was used for normalization. 
Data are represented as the mean fold induction ± SEM; *P < 0.05. (b) Uterine sections obtained 
from vehicle- and BPA-treated mice were subjected to immunohistochemistry using an antibody 
specific for HAND2. HAND2 expression is indicated by the brown color. [Magnification, ×20 
(top), ×40 (bottom)]. HAND2
+
 cells were counted using ImageJ software and expressed as a 
percentage of total cells in the counting field. Data are represented as the mean percentage ± 
SEM; *P < 0.05. (c) RNA isolated from vehicle- and BPA-treated mice was subjected to qPCR 
using primers specific to PR. 36b4 was used for normalization. Data are represented as the mean 
fold induction ± SEM. (d) Uterine sections obtained from vehicle- and BPA-treated mice were 
subjected to immunohistochemistry using an antibody specific for PR (red) and counterstained 










Figure 2.4 Chronic BPA exposure alters FGF signaling in the glandular epithelium 
(a) RNA isolated from vehicle- and BPA-treated (60 µg/kg/d for 60d) mice was subjected to 
qPCR using primers specific to Fgf9 and Fgf18. 36b4 was used for normalization. Data are 
represented as the mean fold induction ± SEM; *P < 0.05. (b) Uterine sections obtained from 
vehicle- and BPA-treated mice were subjected to immunohistochemistry using an antibody 
specific to phosphorylated FRS2 (red, left) as an indicator of FGFR activation or phosphorylated 







Figure 2.5 BPA induces FGF expression in vitro via estrogen receptor  
(a) Primary murine uterine stromal cells were isolated and stimulated in vitro with vehicle 
(ethanol) or 5 µM BPA for 48 h. RNA was isolated and subjected to qPCR using primers 
specific to Fgf9 and Fgf18. 36b4 was used for normalization. Data are represented as the mean 
fold induction ± SEM; *P < 0.05. (b) Primary murine uterine stromal cells were isolated and 
stimulated in vitro with 5 µM BPA in the presence or absence of 10 µM ICI 182,780 for 48 h. 
RNA was isolated and subjected to qPCR using primers specific to Fgf9 and Fgf18. 36b4 was 






Figure 2.6 BPA induces differential methylation at the Hand2 promoter 
(a) Genomic DNA isolated from vehicle- and BPA-treated (60 µg/kg/d for 60 d) uteri was 
subjected to enzymatic digestion as described in “Materials and Methods”; SssI- and SAM-
treated genomic DNA was used to generate hypermethylated DNA as a positive control. 
Digested DNA was subjected to qPCR using primers targeting the indicated Hand2 CpG islands. 
Data are represented as the mean percent methylated input DNA ± SEM; *P < 0.05. (b) Mouse 
uterine stromal cells were placed in culture and treated with 10 µM SAM or vehicle for 24 h. The 
treatment was supplemented with 1 μM of progesterone for 12 h to induce Hand2 expression. 
Genomic DNA was isolated and subjected to enzymatic digestion as described in “Materials and 
Methods” and subjected to qPCR using primers targeting the Hand2 CpG islands 110765 or 
110766, shown in (a). Representative data are shown as mean percent methylated input DNA. (c) 
RNA isolated from mouse uterine stromal cells treated as described in (b) was subjected to qPCR 
using primers specific to Hand2 and Dnmt3b. 36b4 was used for normalization. Representative 





Figure 2.7 BPA induces expression of DNA methylation factors 
(a) RNA isolated from vehicle- and BPA-treated mice was subjected to qPCR using primers 
specific to Dnmt1, Dnmt3b, Mbd2, Mbd3, and Mecp2; 36b4was used for normalization. (b) 
Primary murine uterine stromal cells were isolated and stimulated in vitro with vehicle (ethanol) 
or 5 µM BPA for 48 h. RNA was isolated and subjected to qPCR using primers specific 
to Dnmt1, Dnmt3b, and Mbd2. 36b4 was used for normalization. (c) Mouse uterine stromal cells 
were placed in culture and stimulated with 5 μM BPA in the presence or absence of 10 μM ICI 
182,780 for 48 hours. RNA was isolated and subjected to qPCR using primers specific 
to Dnmt1 and Dnmt3b; 36b4 was used for normalization. (a)–(c) Data are represented as the 






Figure 2.8 Proposed mechanism of BPA action in the mature murine uterus 
BPA reduces stromal expression of the PR target HAND2, possibly through increased DNA 
methyltransferase expression and hypermethylation and gene silencing at the Hand2 promoter. 
As HAND2 is a negative regulator of FGF production, loss of HAND2 allows enhanced FGF 








BPA, bisphenol-A; DAPI, 4′,6-diamidino-2-phenylindole; DNMT, DNA methyltransferase; E, 
estrogen; ER, estrogen receptor; ERK1/2, extracellular signal-regulated kinase 1/2; FGF, 
fibroblast growth factor; FGFR, FGF receptor; FRS2, FGFR substrate 2; HAND2, heart and 
neural crest derivatives expressed 2; MAPK, mitogen activated protein kinase; MBD, methylated 
DNA binding protein; P, progesterone; PR, progesterone receptor; SAM, S-adenosylmethionine 
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CHAPTER 3: Insulin Signaling via Progesterone-dependent Insulin Receptor Substrate 2 




Decidualization, the process by which fibroblastic endometrial stromal cells proliferate 
and subsequently differentiate into secretory decidual cells, is a critical event during the 
establishment of pregnancy. It is dependent on the steroid hormone progesterone acting through 
the nuclear progesterone receptor (PR). Previously, we identified insulin receptor substrate 2 
(IRS2) as a factor that is directly regulated by PR during decidualization. IRS2 is an adapter 
protein that functionally links receptor tyrosine kinases, such as insulin receptor (IR) and insulin-
like growth factor 1 (IGF1) receptor (IGF1R), and their downstream effectors. During in vitro 
decidualization, IRS2 expression was induced within 24 hours of stimulation with estrogen, 
progesterone, and cAMP. siRNA-mediated down-regulation of IRS2 transcripts in HESC 
resulted in attenuation of decidualization, indicating a critical role for IRS2 during this process. 
Further use of siRNAs targeted to IR or IGF1R transcripts showed that down-regulation of IR, 
but not IGF1R, led to impaired decidualization. siRNA-mediated knockdown of IRS2 transcripts 
in HESC suppressed phosphorylation of both ERK1/2 and AKT, downstream effectors of insulin 
signaling, which mediate gene expression associated with decidualization and regulate glucose 
uptake. Indeed, loss of IRS2 resulted in reduced expression and membrane localization of 
glucose transporters GLUT1 and GLUT4, resulting in lowered glucose uptake during stromal 
decidualization. Collectively, these data suggest that the PR-regulated expression of IRS2 is 
necessary for proper insulin signaling controlling gene expression and glucose metabolism, 
which critically support the decidualization process to facilitate pregnancy. This study provides 
new insight into the mechanisms by which steroid hormone signaling intersects with insulin 
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signaling in the uterus during decidualization, which has important implications for pregnancy 
complications associated with insulin resistance and infertility. 
INTRODUCTION 
Infertility is a common issue faced by couples trying to conceive, and therefore it is 
critical to understand the events occurring during early pregnancy to help improve assisted 
reproductive technology. In women, the uterus prepares for pregnancy with each menstrual 
cycle. During the proliferative phase of the menstrual cycle, estrogen (E) produced by the ovaries 
drives proliferation of the endometrium. During the secretory phase, rising levels of progesterone 
(P) produced from the corpus luteum promote differentiation of the stromal cells, a process 
called decidualization. In humans, decidualization is critical to facilitate embryo implantation in 
the event of pregnancy, and impaired decidualization can lead to pregnancy loss. 
During decidualization, under the direction of E and P, stromal cells undergo a 
transformation from spindle shaped fibroblasts to enlarged epithelioid-like decidual cells. 
Decidual cells produce and secrete factors to modulate the activities of uterine vascular 
endothelial cells, epithelial cells, and immune cells to help protect and nurture the embryo during 
early pregnancy (1, 2). Several rodent models have demonstrated that impaired decidualization 
often correlates with subfertility or infertility (3). Because this process is necessary for successful 
pregnancy, it is critical to understand what uterine factors are involved in driving 
decidualization.  
Progesterone signaling though the progesterone receptor (PR) is essential for 
decidualization (4). PR is a member of the nuclear receptor superfamily of transcription factors 
and regulates gene expression upon hormone binding. To better understand the role of PR 
signaling in the uterus, our lab and another have performed ChIP-Seq to identify regions in the 
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human genome bound by PR during decidualization of primary human endometrial stromal cells 
(HESC) (5). These studies both identified insulin receptor substrate 2 (IRS2) as a direct target of 
PR during HESC decidualization. IRS2 expression is induced in response to progesterone and 
can be reduced by siRNA-mediated knockdown of endogenous PR (5). The purpose of this study 
is to further elucidate the role of IRS2 during decidualization.  
IRS2 is part of a family of large docking proteins called insulin receptor substrates (IRS) 
and serves as a cytoplasmic signaling molecule that mediates the downstream signaling of 
insulin and IGF1 receptor tyrosine kinases (RTK) (6). Phosphorylation of IRS2 by these RTKs 
activates two main pathways: the MAPK cascade to regulate transcriptional activity and the 
PI3K/AKT pathway to regulate glucose influx, glycogen synthesis, and transcriptional activity 
(7). Mice lacking IRS2 through global deletion of the Irs2 gene exhibit peripheral insulin 
resistance and -cell deficiency, culminating in a diabetic phenotype (8). Irs2 null mice also 
showed reduced circulating steroid hormones and gonadotropins, ovarian defects, and severely 
reduced fertility, indicating an important role for IRS2 in reproductive function (9).  
Based on insights gained from the rodent model, it is likely that IRS2 plays a critical role 
during human pregnancy as well, although little is known about the function of IRS2 in the 
uterus. Because the Irs2-null mouse exhibits symptoms of type 2 diabetes, we hypothesize that 
the PR target IRS2 facilitates decidualization by mediating local insulin signaling to promote 
glucose uptake to meet the increasing energy demands of the decidual cell. We found that loss of 
IRS2 impairs decidualization of HESC, decreases expression of glucose transporters, and 
reduces glucose uptake during in vitro decidualization. Our results offer insight into insulin 
receptor/IRS2 signaling in the uterus and implicate dysregulation of IRS2 as a contributing factor 
to early pregnancy loss.  
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MATERIALS AND METHODS 
Primary human endometrial stromal cell culture 
Endometrial samples from the early proliferative stage of the menstrual cycle were 
obtained by pipelle biopsy at Emory University and Wake Forest Medical Centers from fertile, 
regularly cycling women under anesthesia before laparoscopy as described previously (10). 
Donors displayed no signs of endometrial pathological conditions and provided written informed 
consent. The subjects ranged in age from 28 to 42 years and in parity from 1 to 2. Primary 
human endometrial stromal cell cultures (HESC) were isolated from the samples as described 
previously (10). HESC were cultured in DMEM/F-12 medium (Gibco) supplemented with 5% 
(v/v) fetal bovine serum (Atlanta Biologicals), 50 μg/mL penicillin, and 50 μg/mL streptomycin 
(Invitrogen). For in vitro decidualization, the cells were treated with a decidualization cocktail 
(DC) composed of 0.5 mM 8-bromo-adenosine-3′,5′-cyclic monophosphate (8-Br-cAMP) 
(Sigma-Aldrich), 1 μM progesterone (Sigma-Aldrich), and 10 nM 17β-estradiol (Sigma-Aldrich) 
in DMEM/F-12 medium (Invitrogen) supplemented with 2% (v/v) charcoal dextran–stripped 
fetal bovine serum (Atlanta Biologicals). In certain experiments, cells were pre-treated for 1 hour 
with 100nM MK2206 (ApexBio), 10µM U0126 (Promega), or 5µM rosiglitazone (Cayman 
Chemicals) before being co-treated with the respective compound and DC. The 
medium/decidualization cocktail/indicated compound was refreshed every 48 hours. 
siRNA mediated knockdown 
HESC were transfected with siRNA targeting IRS2, IR, or IGF1R transcripts 
(Dharmacon) or control scrambled siRNA (Dharmacon) following the manufacturer's protocol 
(Transfectin; Bio-Rad Laboratories). In brief, a final concentration of 50 nM siRNA was mixed 
with Transfectin lipid reagent to transfect the cells. Cells were incubated with siRNA for 24 
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hours and then the media was replaced with DC to induce decidualization. Cells were stimulated 
with DC for 24-72h with media refreshed every 48h.   
RNA isolation and real time PCR analysis 
Total RNA was extracted from cultured HESC using TRIzol (Invitrogen) according to the 
manufacturer's instructions. Total RNA was converted to cDNA using the AffinityScript 
Multiple Temperature Reverse Transcriptase kit (Agilent), following the manufacturer's 
instructions. cDNA was subjected to quantitative PCR analysis using Power Sybr Green PCR 
master mix (Applied Biosystems) and gene-specific primers (IDT Integrated DNA 
Technologies). 36B4 was used as the reference gene. For a given sample, threshold cycle (Ct) 
and SD were calculated as an average of individual Ct values from 3 replicates. The normalized 
mean Ct (ΔCt) was calculated by subtracting the mean Ct of the reference gene 36B4 from the 
mean Ct of a target gene. The ΔΔCt was then calculated for each gene as a difference in ΔCt 
values between the control and the experimental sample. Fold change in gene expression was 
then computed as 2
−ΔΔC
t. The mean fold induction and SEM were calculated from 3-5 
independent experiments. 
Western blot analysis 
Primary HESC were subjected to different treatments conditions as described in the 
figure legends. Whole-cell extracts were prepared using RIPA lysis buffer containing Complete 
Protease Inhibitor Cocktail (Roche) and HALT Phosphatase Inhibitor Cocktail (Thermo Fisher). 
Membrane associated proteins were isolated using Mem-PER Plus Membrane Protein Extraction 
kit (Pierce) per manufacturer’s instruction. Equal amounts of proteins were analyzed by SDS-
PAGE and transferred to polyvinylidene difluoride membrane (Amersham) and the specific 
proteins were detected by Western blotting using antibodies against IRS2 (Abcam), calnexin 
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(Santa Cruz; RRID:AB_2243890) (11), IGFBP1 (Santa Cruz; RRID:AB_2123081) (12), BMP2 
(Proteintech; RRID:AB_10641999) (13), WNT4 (Proteintech; RRID:AB_2215428) (14), 
HAND2 (Millipore), AKT (Santa Cruz; RRID:AB_671714) (15), phosphorylated AKT (Santa 
Cruz; RRID:AB_2225021) (16), ERK1/2 (Santa Cruz; RRID:AB_2650548) (17), 
phosphorylated ERK1/2 (Santa Cruz; RRID:AB_2141287) (18), GLUT1 (Abcam; 
RRID:AB_10903230) (19), GLUT4 (EMD Millipore; RRID:AB_1587080) (20), Integrin β3 
(Santa Cruz; RRID:AB_647490) (21), HSP90 (Santa Cruz; RRID:AB_2121235) (22). 
Membranes were incubated overnight at 4°C with primary antibodies diluted in 5% milk buffer. 
Next day, membranes were washed with PBST and incubated for 1h at room temperature with an 
appropriate IgG HRP-linked secondary antibody (Cell Signaling Technology; 
RRID:AB_330924; RRID:AB_2099233) (23, 24) diluted in 5% milk buffer. Membranes were 
washed, incubated with SuperSignal® West Femto Maximum Sensitivity Substrate (Pierce), and 
imaged using the iBright chemiluminescent imaging system (Thermo Fisher Scientific). Image J 
software (NIH) was used to perform densitometry analysis.  
Immunocytochemistry 
HESC were plated in chamber slides (Cell Treat) and treated as indicated in the figure 
legend. Cells were fixed with 3.7% formaldehyde and permeabilized with 0.1-0.25% Trixton-X 
(Sigma-Aldrich) in PBS. Following blocking with 5% normal donkey serum (Jackson 
Laboratories) and 1% BSA (Jackson Laboratories) in PBS, cells were incubated at 4°C overnight 
with primary antibodies targeting Ki67 (BD Pharmingen; RRID:AB_393778) (25), 
phosphorylated AKT (16), and phosphorylated ERK1/2 (18). Next day, cells were washed with 
PBS and then incubated with the appropriate Cy3 conjugated secondary antibody (Jackson 
Laboratories; AB_2315777; RRID:AB_2307443) (26, 27).  For some experiments, F-actin 
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filaments were stained using Alexa Fluor 488 Phalloidin (Thermo Fisher; RRID:AB_2315147) 
(28). Cells were mounted with Prolong GOLD mounting medium (Promega) containing 4′,6-
diamidino-2-phenylindole nuclear counterstain. Imaging was performed using an Olympus BX51 
microscope fitted with an Olympus DP71 camera (Olympus). ImageJ software was used to 
perform post-imaging analysis. 
Glucose uptake assay 
HESC were subjected to siRNA knockdown, as indicated above.  These cells were 
stimulated for 72h with DC, with media replacement every 48h. Cells were then washed 3 times 
with PBS and incubated in fresh glucose free DMEM supplemented with 2% CD-FBS 
containing 50µM of a fluorescently labeled glucose analog 2-NBDG (Cayman Chemicals) and 
DC for 1h. Cells were then washed 3 times with PBS. 2-NBDG uptake was detected with 
fluorescent filters designed to detect fluorescein (excitation/emission = 485/535 nm).  Cells were 
then lysed and protein concentration was measured by BCA assay (Pierce). 2-NBDG uptake was 
normalized to total protein. 
Statistical analysis 
Statistical analysis was performed using 3-5 independent samples.  Statistical 
significance was determined using the Students t test. Asterisks denotes significance with a P 
value of <0.05. 
 
RESULTS 
Insulin receptor substrate 2 is required for human stromal cell decidualization 
Previously, we showed that IRS2 is a direct target of PR during stromal cell 
decidualization (5). To establish the pattern of IRS2 expression, HESC were treated with 
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decidualization cocktail (E+P+cAMP; DC). IRS2 expression was induced within 24 hours of 
treatment with DC both at the mRNA and protein level and remained elevated through the 6-day 
treatment period [Fig. 3.1(a-b)]. To determine the role of IRS2 during decidualization, we 
performed siRNA mediated knockdown as indicated in the materials and methods, followed by 
72h stimulation with DC. Using this knockdown strategy, we observed approximately 80% 
reduction of IRS2 (siIRS2) at the mRNA level and reduced levels of IRS2 protein to an 
undetectable concentration, relative to a scrambled siRNA control (siCtrl) [Fig. 3.1(c-d)]. We 
next looked at expression of factors that are induced during decidualization. Loss of IRS2 led to 
significantly reduced expression of decidualization markers IGFBP1, BMP2, WNT4, and 
HAND2 in HESC following 72 hours of stimulation with DC [Fig. 3.2(a)]. PRL expression was 
not significantly altered from control with IRS2 knockdown. Moreover, we observed reduced 
protein expression of IGFBP1, BMP2, WNT4, and HAND2 in whole cell lysates with loss of 
IRS2 compared to control cells, as indicated by western blot [Fig. 3.2(b)].  
Successful stromal decidualization results in changes in cell morphology, shifting from a 
spindly fibroblast cell to a rounded decidual cell. We examined the impact of IRS2 knockdown 
on cell morphology by immunocytochemistry, using phalloidin and DAPI to stain actin filaments 
and nuclei, respectively. Upon stimulation with DC, control cells underwent transformation to 
rounded decidual cells, while cells lacking IRS2 retained much of their fibroblastic shape, 
indicating that decidualization was impaired [Fig. 3.2(c)].  
Another key characteristic of in vitro decidualization is the cessation of stromal 
proliferation with the introduction of cAMP, a key component of our DC treatment. Following 
siRNA knockdown, we treated cells with either E and P or the DC containing cAMP for 24 
hours. Proliferation was assessed using an antibody targeting Ki67, a proliferative marker, and 
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Ki67 positive cells were quantified by ImageJ analysis. No difference in proliferation was 
detected between the siCtrl and siIRS2 cells in either the proliferative (E and P) or 
decidualization (DC) culture conditions [Fig. 3.2(d)], suggesting that IRS2 does not play a 
critical role in regulating HESC proliferation. Taken together, these data demonstrate that loss of 
IRS2 attenuates the gene expression and morphological changes associated with decidualization. 
These results establish IRS2 as a critical mediator of progesterone action during endometrial 
stromal cell decidualization. 
IRS2 acts downstream of the insulin receptor to regulate decidualization 
In various cell types, IRS2 is reported to act as an adaptor molecule for both the insulin 
receptor (IR) and IGF1 receptor (IGF1R).  Expression of both of these tyrosine kinase receptors 
was induced in HESC in response to DC [Fig. 3.3(a)]. To elucidate the role of IGF1R/IRS2 and 
IR/IRS2 signaling during decidualization, we performed siRNA mediated knockdown using 
siRNA targeting IGF1R or IR transcripts. Loss of IGF1R did not affect the expression of 
decidualization markers IGFBP1, BMP2, WNT4, HAND2, or PRL [Fig. 3.3(b)]. siRNA mediated 
loss of IR, however, significantly reduced expression of IGFBP1, BMP2, WNT4, and HAND2, 
but not PRL [Fig. 3.3(c)]. This pattern of gene expression is similar to that observed with 
knockdown of IRS2 [Fig. 3.2(a)].   
The culture conditions used in our in vitro decidualization experiments contain 0.04 
ng/ml of insulin, so we next wanted to see if increasing IR activation through increased 
concentrations of the ligand in the culture medium can enhance decidualization. At 0.1 ng/ml, 
the lowest concentration of insulin utilized, IGFBP1 expression was increased compared to DC 
alone [Fig. 3.3(d)]. At higher concentrations, we observed reduced expression of IGFBP1 and 
WNT4 compared to DC alone. Interestingly, we also saw reduced expression of IR itself, 
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suggesting that excess ligand caused downregulation of the receptor and had similar effects on 
gene expression as those observed with siRNA mediated knockdown of IR. We next treated cells 
with rosiglitazone, an anti-diabetic drug that enhances peripheral insulin sensitivity and glucose 
uptake. Addition of rosiglitazone to the culture media significantly increased expression of 
decidualization markers WNT4, BMP2, and IGFPB1 compared to DC alone [Fig. 3.3(e)]. 
Rosiglitazone also enhanced the DC stimulated expression of IRS2. Together, these data suggest 
that IRS2 acts as part of the IR signaling pathway during stromal decidualization and that this 
pathway is sensitive to hyperinsulinemia. 
Loss of IRS2 reduces PI3K/AKT and MAPK activation in HESC during decidualization  
IR activation in insulin target tissues such as liver, muscle, and fat leads to recruitment 
and phosphorylation of IRS2, which in turn mediates the downstream activation of MAPK 
and/or PI3K/AKT to mediate changes in gene expression and regulate glucose transport into the 
cell (6). Loss of IRS2 in HESC stimulated for 24 hours with DC reduced the phosphorylation of 
both AKT and ERK1/2, as determined by western blot [Fig. 3.4(a)] and immunofluorescence 
[Fig. 3.4(b)]. To determine if PI3K/AKT and/or MAPK activation are required for 
decidualization, we used pharmacological inhibitors MK2206 and U0126 to inhibit AKT and 
ERK1/2 phosphorylation, respectively. Similar to what we observed with either IR or IRS2 
knockdown, co-treatment with DC and either MK2206 or U0126 had no effect on PRL 
expression [Fig. 3.4(c)]. However, IGFBP1 and WNT4 expression were both reduced in response 
to either MK2206 or U0126. Together, these data suggest that both MAPK and PI3K/AKT 




IRS2 regulates GLUT transporter expression and localization during HESC 
decidualization 
Because IR/IRS2 signaling is important for glucose uptake and utilization, we wanted to 
explore how these functions are altered with loss of IRS2 during decidualization. We first looked 
at the RNA and protein expression pattern of glucose transporters in HESC stimulated with DC. 
GLUT1 mRNA [Fig. 3.5(a)] and protein [Fig. 3.5(b)] expression increased within 24 hours of 
DC stimulation and remained elevated throughout the treatment period. GLUT4 mRNA [Fig. 
3.5(a)] and protein [Fig. 3.5(b)] expression was also modestly increased in response to DC. This 
indicates that glucose transporters are induced during decidualization and likely facilitate glucose 
transport into the cell to meet the energy demands of decidualization.  
To examine how IRS2 affects GLUT expression, we performed siRNA mediated 
knockdown of IRS2 and stimulated the cells with DC. Both GLUT1 and GLUT4 mRNA and 
protein levels were decreased with loss of IRS2 compared to control cells, as indicated by gene 
expression analysis [Fig. 3.5(c)] and western blot using whole cell lysates [Fig. 3.5(d)], 
respectively.  To observe how GLUT localization is influenced by IRS2, we isolated membrane 
and cytoplasmic protein fractions and measured expression by western blot. With loss of IRS2, 
we observed reduced expression of GLUT1 in the cytoplasmic fraction [Fig. 3.6(a)]. 
Interestingly, we also saw reduced expression of GLUT1 and GLUT4 in the membrane protein 
fraction [Fig. 3.6(a)]. Similar observations were made using immunofluorescence. Following 
knockdown and treatment with DC, we stained cells with either GLUT1 or GLUT4 (red) and 
used phalloidin to stain F-actin filaments to visualize the outer boundaries of the cells (green). 
We observed membrane expression of GLUT1 and GLUT4 in our control cells following 
stimulation with DC [Fig. 3.6(b)], as indicated by the yellow color representing overlap between 
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the respective GLUT and F-actin; this was less apparent with loss of IRS2. Taken together, these 
data demonstrate that IRS2 is necessary for proper GLUT expression and membrane localization 
during decidualization.  
Signaling via IRS2 controls glucose uptake during HESC decidualization 
Since glucose movement into the cell is controlled by glucose transporters, we next 
investigated changes in glucose uptake with loss of IRS2. Following knockdown, cells were 
treated for 72 hours with DC and then exposed to the fluorescently labeled glucose analogue 2-
NBDG, as described in the materials and methods. We found that siIRS2 cells exhibited reduced 
2-NBDG uptake compared to siCtrl cells, suggesting that glucose uptake is impaired with loss of 
IRS2 [Fig. 3.7(a)]. To better understand the effects of glucose availability on decidualization, we 
stimulated HESCs with DC in the presence of reduced concentrations of glucose in the media.  
We observed a decreased expression of IGFBP1 and WNT4 with reduced glucose concentrations 
compared to our normal treatment media [Fig. 3.7(b)], suggesting that reduced glucose 
availability impairs decidualization. 
Collectively, these data suggest that insulin signaling via IRS2 plays a critical role in 
decidualization by regulating GLUT transporter expression and membrane localization to 




Little is known about the function of insulin signaling in the uterus. The aim of this study 
was to better understand how IRS2, a mediator of insulin signaling, impacts decidualization, the 
process of endometrial stromal differentiation that is required for maintenance of pregnancy. 
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Previously, we identified IRS2 as a direct target of PR signaling in primary HESC and showed 
PR occupancy at two regions (-88kb and -307Kb) upstream of the IRS2 transcription start site in 
HESC during decidualization (5). Indeed, we see that IRS2 is induced in HESC with the 
introduction of a decidualization cocktail containing estrogen, progesterone, and cAMP (DC) 
[Fig. 3.1(a-b)]. Stromal cells undergo several changes during their transformation to decidual 
cells, including cessation of proliferation, changes in gene expression (including induction of 
decidual markers IGFPB1, PRL, and WNT4), and a morphological shift from a fibroblastic cell 
type to an epithelioid cell type. We found that loss of IRS2 via siRNA mediated knockdown 
blunted the expression of decidual markers [Fig. 3.2(a-b)] and led to retention of a fibroblastic 
cell shape characteristic of undifferentiated HESC [Fig. 3.2(c)], indicating that IRS2 function is 
essential for decidualization.  
IRS2 functions as an adaptor molecule bridging receptor tyrosine kinases like insulin 
receptor (IR) to downstream signaling proteins. In the uterus, IR expression has been detected in 
the stroma of human endometrial tissue biopsies taken in the secretory phase of the menstrual 
cycle and stromal cells decidualized in vitro, although its role is unclear (29, 30, 31). Findings 
from previous in vitro studies are somewhat contradictory as to whether insulin signaling 
promotes or impairs decidualization (32, 32, 34). Our present study establishes a clear 
requirement for IR expression in stromal decidualization [Fig. 3.3(c)]. Consistent with this 
finding, stimulation of HESC with increasing concentrations of insulin, which resulted in 
reduced IR expression, impaired decidualization [Fig. 3.3(d)]. IR downregulation in response to 
hyperinsulinemic conditions has been demonstrated both in vitro and in vivo and is a 
contributing factor of insulin resistance (6). Moreover, epidemiological studies suggest a link 
between insulin resistance and an increased risk of spontaneous miscarriage and recurrent 
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pregnancy loss (35, 36). In light of these observations, it appears that insulin signaling is tightly 
regulated in the uterus, and its dysregulation during early pregnancy may be a contributing factor 
towards infertility in women presenting with peripheral insulin resistance. 
Signaling through IR/IRS2 leads to downstream activation of PI3K/AKT and MAPK 
pathways to regulate glucose influx, glycogen synthesis, and gene expression to control cell 
growth, proliferation, and differentiation in target tissues (6). In the present study, loss of IRS2 
during decidualization led to reduced MAPK and PI3K/AKT activation [Fig. 3.4(a-b)]. Our 
studies using pharmacological inhibition of ERK activation confirms earlier observations 
indicating a role for MAPK signaling in mediating decidualization [Fig. 3.4(c)] (37). The role of 
PI3K/AKT activity during decidualization is less clear. Immunohistochemical analysis of human 
tissue samples indicated that phosphorylated AKT in the stroma is low in the proliferative and 
early secretory phase of the uterine cycle, but increases in late secretory phase and in decidual 
tissues (38). Other groups have demonstrated that AKT phosphorylation decreases during in 
vitro stromal decidualization (39, 40). Reduced PI3K/AKT activity is necessary for increased 
nuclear accumulation and transcriptional activity of FOXO1, which can regulate gene expression 
of decidual markers (41). However, AKT also plays a critical role in glucose metabolism through 
its regulation and localization of glucose transporters as well as increasing glycogen synthesis 
through inhibition of glycogen synthase kinase (42).  Increased glucose uptake and formation of 
intracellular glycogen stores occur during decidualization, suggesting that some level of AKT 
activation is required to mediate these functions. Our studies indicated that phosphorylation-
dependent AKT activation is impaired in the absence of IRS2 function, leading to inhibition of at 
least certain of the decidualization-associated factors, such as WNT4 [Fig. 3.4(a-c)].  In light of 
these observations, AKT activity during decidualization is more nuanced and may involve a fine 
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balance in phosphorylation/activation to support both its downstream transcriptional and 
metabolic effects.  
One of the major functions of insulin signaling is to promote movement of glucose from 
the blood into the cell through integral membrane transporters called glucose transporters 
(GLUT).  The facilitative GLUT transporter family is comprised of 14 GLUT protein family 
members with varying kinetics, regulatory properties, and tissue expression patterns (43). The 
presence of several GLUT family members was reported in the endometrium, but the most 
abundant is GLUT1 (44). GLUT1 is robustly expressed in the stroma during the secretory phase 
of the uterine cycle and in the decidua (31, 46). We observed an increased stromal GLUT1 
expression induced by progesterone, estrogen, and cAMP, which reflects its pattern of 
expression during the secretory phase [Fig. 3.5(a-b)]. Reduced stromal expression of GLUT1 has 
been observed in women suffering from idiopathic infertility compared to those whose infertility 
is independent of endometrial function, such as tubal occlusion or male infertility (45). Our study 
finds that IRS2 is necessary for GLUT1 expression during decidualization [Fig. 3.5(c-d)]. While 
the insertion of GLUT1 into the cell membrane is not considered to be an insulin dependent 
process, insulin, as well as MAPK and PI3K/AKT activity, have been shown to stimulate 
GLUT1 expression in muscle, liver, fat, and mesangial cells (46, 47, 48, 49, 50). Disruption of 
IR signaling through loss of IRS2 impairs GLUT1 production and decreases the reserve of 
GLUT1 transporters, leading to its decreased presence at the membrane [Fig. 3.6(a-b)].  
 In contrast to GLUT1, less is known about uterine GLUT4. Tissue analysis studies report 
GLUT4 is weakly expressed in uterine stromal cells (51). GLUT4 is considered insulin 
dependent in that insulin stimulates GLUT4 insertion at the cell membrane. Consistent with this, 
loss of IRS2 reduced the accumulation of GLUT4 in the cell membrane [Fig. 3.6(a-b)]. Although 
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its expression during decidualization is less robust than that of GLUT1, perturbations in the 
temporal distribution of GLUT4 likely contribute to the overall reduction of glucose uptake 
observed with loss of IRS2.  
The increase in stromal GLUT expression suggests a functional relevance of increased 
glucose usage during decidualization. Indeed, previous reports indicated that glucose uptake is 
increased in endometrial stromal cells undergoing in vitro decidualization (33, 44). As shown in 
Fig. 3.7(b), culturing HESC in reduced glucose impaired decidualization. IRS2 clearly supports 
increased glucose flux into HESC [Fig. 3.7(a)], although other signaling mediators are likely to 
be involved. Once in the stromal cell, glucose is shuttled through several metabolic pathways, 
including glycolysis to provide energy in the form of ATP and the pentose phosphate pathway to 
aid in cholesterol, fatty acid, and nucleotide synthesis (52, 53). Future work is needed to 
establish how IRS2 acts in concert with other insulin receptor signaling components to impact 
the shuttling of glucose during decidualization of HESC.  
Several endocrine conditions associated with insulin resistance have been linked to 
pregnancy complications. Polycystic ovarian syndrome (PCOS) is a condition characterized by 
hyperandrogenism and hyperinsulinemia that can reflect insulin resistance in peripheral tissues. 
A retrospective study performed among PCOS patients suggests that those with accompanying 
insulin resistance have an increased risk of miscarriage than patients who do not exhibit insulin 
resistance (54). Metformin is a common treatment for PCOS and other manifestations of type 2 
diabetes to improve insulin sensitivity and alleviate hyperinsulinemia. PCOS patients who 
continued taking metformin during their pregnancy showed a reduced rate of early pregnancy 
loss compared to PCOS patients that stopped taking the drug upon determination of pregnancy 
(55, 56). Gestational diabetes mellitus (GDM), a condition manifesting towards the end of the 
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second trimester, is also characterized by maternal insulin resistance and insufficient production 
of insulin to overcome this resistance. Analysis of post-partum placental tissues from women 
who presented with GDM showed reduced expression of glucose transporters and components of 
the insulin signal transduction pathway compared to control tissue from healthy pregnant women 
(57). Interestingly, Ayaz et al., 2014 observed a link between the IRS2 G1057D polymorphism, 
which has diminished capacity to associate with downstream signaling molecules, and increased 
risk for developing GDM, suggesting that impaired signaling through IRS2 may contribute to the 
manifestation of GDM (58, 59).  
 
CONCLUSION 
Our study establishes a critical role for the PR target IRS2 in mediating IR signaling 
during HESC decidualization [Fig. 3.8]. IRS2 acts downstream of the IR and is required for 
MAPK activation that is critical for decidualization-specific gene expression. IRS2 also controls 
activation of AKT and expression of glucose transporters, thereby modulating cellular glucose 
uptake that meets the energy demands of the decidualization process. This study provides insight 
into the regulation of glucose metabolism in the uterus by the concerted actions of steroid 
hormone progesterone and insulin and it increases our understanding of the underlying 










Figure 3.1 IRS2 is expressed in HESC during decidualization  
IRS2 mRNA (a) and protein (b) expression was observed in HESC treated with DC 
(E+P+cAMP) for 0-6 days. (a) Gene expression analysis was performed using primers specific 
for IRS2. 36B4 was used for normalization. Data are represented as the mean fold induction  
SEM. *, P<.05 relative to day 0. (b) Whole cell lysates were analyzed by western blot and 
probed with antibody specific to IRS2. Calnexin is provided as a loading control. Densitometry 
analysis is provided (below). (c) Following siRNA mediated knockdown of IRS2 and stimulation 
with DC for 72h, gene expression analysis was performed using primers specific to IRS2. 36B4 
was used for normalization. Data are represented as the mean fold induction  SEM. *, P<.05 
relative to siCtrl.  (d) Following knockdown and stimulation with DC for 72h, IRS2 expression 
was determined by western blot. Calnexin is provided as a loading control. Densitometry 











Figure 3.2 IRS2 is required for human stromal cell decidualization  
(a) Gene expression analysis was performed following IRS2 knockdown and 72h stimulation 
with DC using primers specific for IGFBP1, BMP2, WNT4, HAND2, and PRL. 36B4 was used 
for normalization. Data are represented as the mean fold induction  SEM. *, P<.05 relative to 
siCtrl. (b) Following knockdown and stimulation with DC for 72h, IGFBP1, BMP2, WNT4, and 
HAND2 expression was determined by western blot. Calnexin is provided as a loading control. 
Densitometry analysis is provided (below). (c) IRS2 knockdown was performed and cells were 
stimulated for 6 days with DC and stained with phalloidin to bind actin filaments. DAPI was 
used as a nuclear stain. Images provided are x40 magnification. (d) IRS2 knockdown was 
performed and cells were exposed for 24h of proliferative (E+P) and differentiating  
70 
 
Figure 3.2 continued: (DC; E+P+cAMP) conditions. Immunofluorescent staining of Ki67 was 
performed and DAPI was used as a nuclear stain. Ki67 positive cells were counted using ImageJ 





Figure 3.3 IRS2 acts downstream of the insulin receptor (IR) to regulate decidualization 
(a) Gene expression analysis was performed with RNA isolated from HESC treated with vehicle 
(ethanol) or DC for 72h using primers specific to IGF1R and IR. 36B4 was used for 
normalization. Data are represented as the mean fold induction  SEM. *, P<.05 relative to 
vehicle. Following siRNA mediated knockdown of IGF1R (b) or IR (c) and stimulation with DC 
for 72h, gene expression analysis was performed using primers for IGFBP1, BMP2, WNT4,  
HAND2, and PRL. 36B4 was used for normalization. Data are represented as the mean fold  
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Figure 3.3 continued: induction  SEM. *, P<.05 relative to siCtrl. (d) HESC were co-
stimulated with DC and the indicated concentration of insulin for 72 hours. Gene expression 
analysis was performed using primers for IGFBP1, WNT4, and IR. 36B4 was used for 
normalization. Data are represented as the mean fold induction  SEM. *, P<.05 relative to DC 
alone. (e) Gene expression analysis was performed with RNA isolated from HESC treated with 
DC with or without 5M rosiglitazone (Rosi) for 72h using primers specific to IGFBP1, BMP2, 
WNT4, HAND2, and IRS2. 36B4 was used for normalization. Data are represented as the mean 





Figure 3.4 Loss of IRS2 reduces PI3K/AKT and MAPK activation in HESC during 
decidualization 
Following siRNA mediated knockdown of IRS2 and 24h stimulation with DC, protein expression 
was investigated by western blot (a) and immunofluorescence (b). (a) Whole cell lysates were 
analyzed by western blot and probed with antibodies specific for phosphorylated and total 
ERK1/2 and phosphorylated and total AKT. Calnexin was used as a loading control. 
Densitometry analysis is provided (right). (b) Immunofluorescent staining using antibodies 
specific for phosphorylated ERK1/2 and phosphorylated AKT. DAPI was used as a nuclear stain. 
Images provided are x40 magnification. (c) Gene expression analysis was performed with RNA  
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Figure 3.4 continued: isolated from HESC treated with DC and DMSO or either 10M U0126 
or 100nM MK2206 for 72h using primers specific for IGFBP1, WNT4, and PRL. 36B4 was used 






Figure 3.5 IRS2 regulates GLUT transporter expression during decidualization 
GLUT mRNA (a) and protein (b) expression was observed in HESC treated with DC for 0-6 
days. (a) Gene expression analysis was performed using primers specific for GLUT1 and 
GLUT4. 36B4 was used for normalization. Data are represented as the mean fold induction  
SEM. *, P<.05 relative to day 0. (b) Whole cell lysates were analyzed by western blot and 
probed with antibodies specific to GLUT1 and GLUT4. Calnexin is provided as a loading 
control. Densitometry analysis is provided (below). GLUT mRNA (c) and protein (d) expression 
was observed in HESC stimulated for 72h with DC following siRNA mediated knockdown of 
IRS2. (c) Gene expression analysis was performed using primers specific for GLUT1 and 
GLUT4. 36B4 was used for normalization. Data are represented as the mean fold induction  
SEM. *, P<.05 relative to siCtrl. (d) Whole cell lysates were analyzed by western blot and 
probed with antibodies specific for GLUT1 and GLUT4. Calnexin is provided as a loading 





Figure 3.6 IRS2 promotes membrane localization of GLUTs during decidualization  
HESC were treated for 72h with DC following siRNA mediated knockdown of IRS2. Membrane 
associated GLUT expression was observed using western blot (a) and immunofluorescence (b). 
(a) Membrane associated and cytoplasmic protein fractions were isolated as described in 
materials and methods. These fractions were subjected to western blot and probed with 
antibodies for GLUT1 and GLUT4. Integrin β3 and HSP90 were used as fraction-specific 
controls. Densitometry of membrane fraction is provided (right). (b) Immunofluorescent staining 
using antibodies specific for GLUT1 and GLUT4. DAPI was used as a nuclear stain and 





Figure 3.7 Loss of IRS2 reduces glucose uptake by HESC undergoing decidualization 
(a) HESC were treated for 72h with DC following siRNA mediated knockdown of IRS2. Cells 
were switched to a glucose free medium for 1h prior to addition of 50M of 2-NBDG for 1h. 
Cells were washed and 2-NBDG incorporation was measured and normalized to total protein. 
Data are represented as the mean fold glucose uptake  SEM. *, P<.05 relative to siCtrl. (b) 
HESC were stimulated with DC in the presence of full (100%; 17.5mM) or reduced (75 and 
50%; 13 and 8.75mM, respectively) glucose concentrations in the culture media for 72h. Gene 
expression analysis was performed using primers specific for IGFBP1 and WNT4. 36B4 was 
used for normalization. Data are represented as the mean fold induction  SEM. *, P<.05 relative 





Figure 3.8 Potential mechanism by which the PR target IRS2 promotes decidualization 
During decidualization, PR induces IRS2 expression. IRS2 acts as an adaptor to insulin receptor, 
leading to downstream activation of MAPK and PI3K/AKT pathways, and increased expression 
of decidualization markers and glucose transporters. These GLUTs transport glucose into the cell 









BMP2, bone morphogenetic protein 2; E, estrogen; ERK, extracellular-signal regulated kinase; 
DC, differentiation cocktail; GDM, gestational diabetes mellitus; GLUT, glucose transporter; 
HAND2, heart and neural crest derivatives expressed 2; HESC, human endometrial stromal cells; 
IGF1, insulin like growth factor 1; IGF1R, IGF1 receptor; IGFBP1, insulin like growth factor 
binding protein 1; IR, insulin receptor; IRS2, insulin receptor substrate 2; MAPK, mitogen 
activated protein kinase; PCOS, polycystic ovarian syndrome; PI3K/AKT, phosphoinositide 3-
kinase/AKT; P, progesterone; PR, progesterone receptor; PRL, prolactin; RTK, receptor tyrosine 
kinase; WNT4, wingless-type MMTV integration site family, member 4 
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CHAPTER 4: Future Studies 
 
 
FUTURE STUDIES FOR CHAPTER 2 
Analysis of differential methylation of uterine epigenome following BPA exposure of mice 
The study in chapter 2 demonstrates that long term oral exposure to the environmental 
toxicant BPA at a concentration deemed by the EPA to be safe for human exposure is linked to 
physiological changes conducive to the development of endometrial hyperplasia and cancer. This 
included suppression of the anti-proliferative factor HAND2, leading to excessive proliferation. 
Our study reveals BPA induced expression of DNA methyltransferases (DNMT) and methylated 
DNA binding protein (MBD) and increased methylation at the Hand2 promoter. We chose to 
focus on HAND2 specifically because of its anti-proliferative function; however, it is likely that 
multiple genes are differentially methylated following BPA exposure. Other groups have 
demonstrated differential methylation at other target genes, including Esr1, Gck, and Pgc1α 
following BPA exposure (1,2,3,4). However, these previous studies were performed in rodents 
exposed to BPA during critical windows of development and analysis was often restricted to 
male subjects. It would be interesting in a future study to take a comprehensive look at factors 
that are differentially methylated in the uterus following adult exposure to BPA. To do this, we 
would like to perform methylated DNA immunoprecipitation (MeDIP) on uterine tissue from 
vehicle and BPA treated mice using an antibody against 5-methylcytosine, followed by high 
throughput sequencing. This would provide us with an unbiased report of differentially 
methylated genes. We can then use RNA-seq to identify targets that are differentially expressed 
in response to BPA. We can also confirm transcriptional repression due to hypermethylation by 
observing MBD2 occupancy at hypermethylated sites. We can then use programs like DAVID to 
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classify these targets by biological categories to observe what cellular functions are promoted or 
suppressed by BPA exposure.  
Effects of combined toxicant exposure on uterine health 
Another aspect we would like to explore is the effect of combined toxicant exposure on 
the uterus. Humans are exposed to multiple endocrine disrupting chemicals throughout the day 
via food packaging, personal care products and occupational exposure. It is possible that 
simultaneous or sequential exposures to these chemicals may have a greater physiological affect 
than an individual chemical (5). Several chemicals have been shown to differentially affect 
uterine weight, including parabens, phthalates, and Bisphenol-A replacements like Bisphenol-B, 
-S, and –AF (6). We propose a series of dosing experiments using combinations of these 
chemicals to observe their net effect on uterine weight and epithelial proliferation. A dosing 
scheme using multiple endocrine disrupting chemicals would be more representative of daily 
human exposure.  
 
FUTURE STUDIES FOR CHAPTER 3 
Mechanisms of Regulation of GLUT expression by IRS2 during decidualization 
 Chapter 3 focuses on the role of IRS2 during stromal decidualization. We report that loss 
of IRS2 reduced GLUT1 and GLUT4 expression. However, since IRS2 is an adaptor molecule 
and does not have inherent transcriptional activity, we were curious how GLUT gene expression 
was regulated. Using pharmacological inhibitors to block downstream activation of MAPK or 
PI3K/AKT, we observed reduced GLUT1 expression [Fig. 4.1]. The induction of GLUT1 gene 
expression via MAPK and PI3K/AKT activation is well documented and could result from the 
activation of downstream transcription factors like CREB or NFB (7,8,9,10,11). Further work is 
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needed to elucidate the exact method of GLUT1 transcriptional regulation. Interestingly, GLUT4 
expression was maintained despite inhibitor treatment suggesting a mechanism distinct from 
GLUT1. Recently, we observed via microarray analysis of stromal cells isolated from Hif2α null 
mice that Glut4 expression is dependent on functional HIF2α (data not shown). HIF2α is a 
transcription factor that is induced in uterine stromal cells undergoing decidualization under the 
control of estrogen (12). HIF2α functions predominantly during conditions of low oxygen, or 
hypoxia, where the protein is further stabilized and accumulates in the nucleus to 
transcriptionally regulate hypoxia inducible genes (13). In vitro, under normoxic conditions 
(20% O2), we observed increased expression of HIF2α in HESC undergoing decidualization 
[Fig. 4.2(a)], while HIF2α expression was reduced with loss of IRS2 [Fig. 4.2(b)]. siRNA 
mediated knockdown of HIF2α reduced expression of GLUT4, but did not affect IRS2 [Fig. 
4.2(c)], suggesting it may act downstream of IRS2. HIF2α was detectable in the nucleus and 
cytoplasm of cells decidualized in normoxia, and its expression increased in hypoxia (3% O2) 
[Fig. 4.3(a)]. We also observed greater induction of GLUT4 in hypoxia compared to normoxia 
[Fig. 4.3(b-c)]. With hypoxia, loss of IRS2 reduced both HIF2α and GLUT4 expression [Fig. 
4.4(a)], whereas, loss of HIF2α reduced GLUT4 without affecting IRS2 expression [Fig. 4.4(b)]. 
Together, these data suggest that in hypoxia HIF2α acts downstream of IRS2 to regulate GLUT4, 
similar to what we observe in normoxia. To explore this interaction further, we performed in 
silico analysis using the Contra V3 software and identified several putative HIF2α binding sites 
within the GLUT4 proximal and distal promoter regions. We plan to perform ChIP-qPCR 
analysis using a HIF2α antibody to determine whether GLUT4 is directly regulated by HIF2α. 
Additionally, we plan to explore the contribution of GLUT4 to decidualization by performing 
siRNA mediated knockdown in normoxic and hypoxic conditions to observe how expression of 
86 
 
decidual markers and glucose uptake is affected. Little is known about the role of GLUT4 during 
the secretory phase of the uterine cycle and the underlying molecular changes occurring in the 
uterine stromal cells. This work would help fill the gaps in our understanding of glucose 










Figure 4.1 MAPK and PI3K/AKT activation are required for GLUT1 but not GLUT4 
expression 
Gene expression analysis was performed with RNA isolated from HESC treated with DC and 
DMSO or either 10M U0126 or 100nM MK2206 for 72h using primers specific for GLUT1 and 
GLUT4. 36B4 was used for normalization. Data are represented as the mean fold induction 






Figure 4.2 HIF2α is induced during decidualization and regulates GLUT4 under normoxia 
HESC were treated with DC (E+P+cAMP) for 0-6 days and gene expression analysis was 
performed using primers specific for HIF2α. 36B4 was used for normalization. Data are 
represented as the mean fold induction relative to d0. Following siRNA mediated knockdown of 
IRS2 (b) or HIF2α (c)and stimulation with DC for 72h, gene expression analysis was performed 
using primers specific to IRS2, HIF2α, and GLUT4. 36B4 was used for normalization. Data are 






Figure 4.3 Hypoxia causes HIF2α accumulation and increased expression of GLUT4 
HESCS were stimulated with DC under normoxia (20% O2) or hypoxia (3% O2) for 72h. (a) 
Immunofluorescent staining was performed using antibody specific for HIF2α. DAPI was used 
as a nuclear stain. Images provided are x40 magnification. (b) Gene expression analysis was 
performed using primers specific for GLUT4. 36B4 was used for normalization. (c) 
Immunofluorescent staining was performed using antibody specific for GLUT4. DAPI was used 






Figure 4.4 HIF2α regulates GLUT4 under hypoxia 
Following knockdown of either IRS2 (a) or HIF2α (b), HESCS were stimulated with DC under 
hypoxia (3% O2) for 72h. Gene expression analysis was performed using primers specific to 
IRS2, HIF2α, and GLUT4. 36B4 was used for normalization. Data are represented as the mean 
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